

CRISPR-Based Approaches for Gene Regulation in Non-Model Bacteria

Stephanie N. Call¹, Lauren B. Andrews^{1,2,3*}

¹Department of Chemical Engineering, University of Massachusetts Amherst

²Biotechnology Training Program, University of Massachusetts Amherst

³Molecular and Cellular Biology Graduate Program, University of Massachusetts Amherst, Amherst, Massachusetts, USA

* **Correspondence:**

Lauren B. Andrews

lbandrews@umass.edu

Keywords: bacterial gene regulation, CRISPR interference (CRISPRi), CRISPR activation (CRISPRa), transcriptional interference, transcriptional activation, non-model bacteria, genome-wide library

Abstract

CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) have become ubiquitous approaches to control gene expression in bacteria due to their simple design and effectiveness. By regulating transcription of a target gene(s), CRISPRi/a can dynamically engineer cellular metabolism, implement transcriptional regulation circuitry, or elucidate genotype-phenotype relationships from smaller targeted libraries up to whole genome-wide libraries. While CRISPRi/a has been primarily established in the model bacteria *Escherichia coli* and *Bacillus subtilis*, a growing number of studies have demonstrated the extension of these tools to other species of bacteria (here broadly referred to as non-model bacteria). In this mini-review, we discuss the challenges that contribute to the slower creation of CRISPRi/a tools in diverse, non-model bacteria and summarize the current state of these approaches across bacterial phyla. We find that despite the potential difficulties in establishing novel CRISPRi/a in non-model microbes, over 190 recent examples across eight bacterial phyla have been reported in the literature. Most studies have focused on tool development or used these CRISPRi/a approaches to interrogate gene function, with fewer examples applying CRISPRi/a gene regulation for metabolic engineering or high-throughput screens and selections. To date, most CRISPRi/a reports have been developed for common strains of non-model bacterial species, suggesting barriers remain to establish these genetic tools in undomesticated bacteria. More efficient and generalizable methods will help realize the immense potential of programmable CRISPR-based transcriptional control in diverse bacteria.

1 Introduction

Since the development of CRISPR interference (CRISPRi) (Qi et al., 2013) and CRISPR activation (CRISPRa) (Bikard et al., 2013) in 2013, they have become efficient and prevalent tools for transcriptional regulation in bacteria. CRISPR-Cas originates as a form of prokaryotic immunity,

with systems comprising one or more CRISPR-associated (Cas) proteins and a short guide RNA (gRNA) that complex together to target and cleave foreign DNA or RNA molecules, such as viruses (Nussenzweig and Marraffini, 2020). The gRNA leads the complex to target sequence via complementarity between the protospacer sequence of the gRNA and the target site on the DNA/RNA molecule. Various mechanisms exist to prevent cleavage of chromosomal DNA, which most often involves a protospacer adjacent motif (PAM) or equivalent next to the target site that is not present in the CRISPR arrays on the chromosome (Jackson et al., 2017).

Researchers developed CRISPRi technology by deactivating the nuclease activity of select Cas enzymes to create mutant dCas proteins that bind, but do not cleave, the DNA target (Qi et al., 2013). Most CRISPRi systems repress a gene's expression through steric inhibition of RNA polymerase binding or extension (Qi et al., 2013), although some repress gene expression through RNA cleavage (Zhang et al., 2020a; Rahman et al., 2021). Gene repression over 100-fold has been reported for several diverse CRISPRi tools and can approach near knockout levels of gene expression (Qi et al., 2013; Miao et al., 2019). Targeting a different sequence is easily achieved by changing the short protospacer sequence on the gRNA to bind a location within the promoter, untranslated region, or coding sequence of the target gene based on simple design rules (Qi et al., 2013; Zetsche et al., 2015; Zhang et al., 2017). Additionally, multiplexed gene repression can be achieved by simply expressing multiple gRNA within a cell (Qi et al., 2013; Zhang et al., 2017).

Shortly after the development of CRISPRi, researchers developed CRISPRa for bacterial transcriptional activation by combining the dCas protein with a transcriptional activator that recruits transcription machinery to the target gene's promoter to increase gene expression (Bikard et al., 2013). The specific mechanism for transcriptional activation depends on the activator, which can be incorporated by directly fusing a transcriptional activator domain to the dCas protein (Bikard et al., 2013; Ho et al., 2020; Schilling et al., 2020), incorporating RNA scaffolds into the gRNA sequence to recruit activator domains to the dCas complex (Dong et al., 2018; Liu et al., 2019b; Fontana et al., 2020a), or using non-covalent protein-protein interaction domains to complex the transcriptional activator and dCas protein (Villegas Kcam et al., 2021; Villegas Kcam et al., 2022). Unlike CRISPRi, however, CRISPRa has complex design rules that often strongly depend on the CRISPRa technology (i.e., type of activation domain and approach to couple the activation domain and dCas complex) as well as several other factors (Liu et al., 2019b; Fontana et al., 2020a; Ho et al., 2020; Villegas Kcam et al., 2021). These other considerations include the basal expression of the target gene and the location of the binding site for the CRISPRa complex, where activation is typically achieved in a narrow range upstream of the target gene's promoter and the activation strength fluctuates sharply as the nucleotide position shifts. Combined with the PAM requirement for DNA binding, these requirements greatly restrict the available DNA target sites for effective gene activation, especially for endogenous genes. Due to these relatively stringent design rules for gene activation and often low (<10-fold) activation levels compared to CRISPRi repression (Bikard et al., 2013; Liu et al., 2019a; Fontana et al., 2020a; Villegas Kcam et al., 2021), CRISPRa development has been slower in bacteria than in eukaryotes (Kampmann, 2018; Fontana et al., 2020b). Despite the current limitations of CRISPRa, however, the simplicity and inherent properties of CRISPRi/a gene regulation can provide strong transcriptional control of multiple genes simultaneously, making these approaches often easier and faster than traditional methods and allowing for dynamic transcriptional control.

CRISPR systems are classified into a variety of classes, types, subtypes, and variants, each with unique genes and properties (Koonin et al., 2017; Makarova et al., 2020). Many systems have been engineered to create effective CRISPRi/a tools. The first and most common tool is derived from the

Type II Cas9 system, which comprises a single deactivated Cas9 (dCas9) protein and two small RNA that create the gRNA (Qi et al., 2013). These two RNAs can be combined into a synthetic single guide RNA (sgRNA) for easier synthesis, but each sgRNA requires an independent promoter for expression (Jiang et al., 2015). Although many different dCas9 variants exist, the *Streptococcus pyogenes* dCas9 (Sp dCas9) system is the most common due to its short PAM sequence and strong transcription regulation abilities. Recently, tools derived from the Type V Cas12a (formerly Cpf1) system have been developed, which uses a single deactivated Cas12a (dCas12a) protein and one gRNA (Zetsche et al., 2015; Kim et al., 2017; Zhang et al., 2017; Miao et al., 2019). Unlike dCas9, dCas12a can process its gRNA from CRISPR arrays, providing easier multiplexed regulation (Fonfara et al., 2016; Zhang et al., 2017). Additionally, several studies have suggested that dCas12a variants are less toxic than dCas9 variants across different bacterial phyla (Liu et al., 2019a; Knoot et al., 2020; Kuo et al., 2020), making them an attractive alternative to dCas9. The most common dCas12a variants used in bacteria are derived from *Francisella tularensis* subsp. *novicida* (Fn dCas12a) and *Acidaminococcus* sp. BV3L6 (As dCas12a). Several Type I CRISPRi/a tools have been designed, but due to the large number of genes in these systems, most tools are implemented by reprogramming the host species' endogenous CRISPR system for gene repression (Luo et al., 2015; Xu et al., 2021; Villegas Kcam et al., 2022). Only a handful of CRISPRi tools from other systems have been reported for transcriptional regulation in bacteria, likely due to the novelty of the system (Rahman et al., 2021) or high cellular toxicity observed upon expression (Zhang et al., 2020a).

Despite the unique traits and relevance of a vast diversity of bacteria, CRISPRi/a tools have been primarily developed in the model bacteria *Escherichia coli* and *Bacillus subtilis*. Yet, non-model bacteria (a broad definition of non-model, excluding *E. coli* and *B. subtilis*, is used here) offer great promise in research and industry spanning a wide range of medical, environmental, and biomanufacturing applications. For example, *Streptomyces*, *Sorangium*, and *Photorhabdus* spp. naturally produce bioactive secondary metabolites, such as antibiotics, and contain silent biosynthetic gene clusters with unknown and potentially useful products (Ye et al., 2019; Tian et al., 2020; Ke et al., 2021). Additionally, *Rhodococcus* and *Corynebacterium* spp. can produce valuable chemicals from cheap and simple feedstock and are tolerant to harsh conditions, making them ideal cell factories (Cleto et al., 2016; DeLorenzo et al., 2018). However, several conditions must be reached to successfully establish efficient CRISPRi/a tools in a non-model bacterium. In this mini-review, we detail these criteria, emphasizing the importance of characterized genetic parts to tightly control the expression of CRISPRi/a systems to limit potential toxicity while providing sufficient expression for effective transcriptional control. We demonstrate that despite the potential difficulties in creating these tools in non-model bacteria, they have been established across eight different bacterial phyla and have been used for a variety of applications, including high-throughput genome-wide selections. Finally, we highlight the current challenges to developing CRISPRi/a tools in non-model bacteria and novel species, which suggest directions for future progress.

Requirements and Challenges to Establish CRISPRi/a in Non-Model Bacteria

Several criteria must be met to successfully establish an effective CRISPRi/a tool in a non-model species or strain. First, the conditions for culturing, maintaining, and genetically manipulating the strain (often referred to as strain “domestication”) must be determined. For a phylogenetically similar strain to a previously established model bacteria, such as many *Bacillus* species (Zhan et al., 2020) and Enterobacteriaceae (Ho et al., 2020), suitable culture conditions may be similar to those previously determined. For novel or fastidious species, however, trial and error and patience may be

required to determine appropriate culture conditions for growth and genetic manipulation, such as the obligate intracellular pathogen *Chlamydia trachomatis* (Ouellette, 2018). Additionally, introducing foreign DNA is often challenging for a non-model bacterium, as many are genetically recalcitrant, especially pathogens (Fernandes et al., 2021b) and novel strains (Zhao et al., 2020; Jin et al., 2022), and establishing a sufficient genetic transformation method can require significant effort. Additionally, care must be taken when introducing synthetic DNA to circumvent the bacterial host's native immunity that may degrade foreign DNA, including restriction-modification and CRISPR systems (Marraffini and Sontheimer, 2008; Jin et al., 2022), such as by mimicking the recipient strain's methylation patterns (Monk et al., 2015; Zhao et al., 2020). More discussion on the isolation and domestication of non-model bacteria can be found in other reviews (Vartoukian et al., 2010; Lewis et al., 2021; Riley and Guss, 2021).

Next, reliable genetic parts for the non-model bacterium are required to be able to express and tightly control the CRISPRi/a tool, including promoters, ribosome binding sites, terminators, and expression or integration vectors. For many non-model bacteria, especially novel species, these genetic part libraries are unavailable, and so, the necessary genetic parts must be created and characterized. In some cases, established genetic parts may be transferable from a model bacterium to a related species, such as promoters between Gram-positive bacteria (Liew et al., 2010). However, genetic parts often do not function equivalently between bacterial species or even strains (Tong et al., 2015; Leonard et al., 2018). Each CRISPRi/a component should be expressed using unique genetic parts to prevent repeated DNA sequences. Since dCas protein expression can elicit cytotoxicity, high strength promoters used for overexpression may not be optimal. If existing genetic parts are insufficient for a new bacterial species, identifying genetic regulatory elements from the endogenous genome provides an alternative to synthetic DNA design strategies (Fernandes et al., 2019). Libraries of genetic parts and inducible promoters are excellent tools to tune the expression of CRISPRi/a systems, and several studies have established such toolboxes in non-model bacteria to facilitate the development of genetic tools such as CRISPRi/a (Mimee et al., 2015; Leonard et al., 2018; Shin et al., 2019; Teh et al., 2019; Liow et al., 2020). These libraries and tunable parts are especially important to control the expression of the CRISPRi/a tool to minimize potential cellular toxicity and to precisely control transcriptional regulation (Qu et al., 2019; Bosch et al., 2021; Shabestary et al., 2021).

In the design of a synthetic CRISPRi/a system for a bacterium, consideration should be given to prevent interference with endogenous CRISPR systems and/or anti-CRISPR genes harbored on the strain's genome. If the foreign and native CRISPR-Cas types are too similar, the introduction of the synthetic gRNA may induce cleavage of the host bacterium's genome (via the catalytically active endogenous Cas enzyme) and can cause cell death in a DNA repair-deficient strain or undesired mutations if the strain has appropriate DNA repair pathways. This can be avoided by choosing a CRISPRi/a tool that does not share significant homology to any endogenous CRISPR-Cas. Native CRISPR-Cas systems can be predicted from the sequenced genome or proteome using computer software (Couvin et al., 2018; Chai et al., 2019), aiding in CRISPRi/a tool selection for novel strains. Alternatively, the native system can be engineered to create a CRISPRi/a tool via genetic manipulation, such as the deletion of the native *cas2/3* or *cas3* gene responsible for cleavage in Type I-F systems (Zheng et al., 2019; Qin et al., 2021; Xu et al., 2021) or mutating the native *cas9* sequence for Type II systems (Shields et al., 2020; Dammann et al., 2021). Anti-CRISPR proteins, which inhibit CRISPR systems through a variety of mechanisms (Pawluk et al., 2018), may require deletion or disruption before a heterologous CRISPRi/a tool can be expressed (Xu et al., 2021). Online tools and databases are available to predict and describe anti-CRISPR proteins from protein sequences to help select an appropriate CRISPRi/a system (Wang et al., 2020, 2021a).

Finally, the CRISPRi/a components should be expressed at a level that provides adequate transcriptional repression or activation for the given application without significant cellular toxicity. Many studies have reported CRISPRi toxicity for diverse bacteria, while little is known about CRISPRa toxicity due to limited reports in the literature. These observed forms of toxicity include changes in cell morphology (Cho et al., 2018; Ouellette et al., 2021) and slower growth or complete growth inhibition (Rock et al., 2017; Yu et al., 2018; Wurihan et al., 2019; Brito et al., 2020; Zhang et al., 2020a). To prevent toxicity, one can use a less toxic CRISPRi/a system for the host species (Rock et al., 2017; Zhao et al., 2019), or reduce the expression of the components by substituting genetic parts (Qu et al., 2019). Expansive libraries of genetic parts, including inducible and constitutive promoters, ribosome binding sites, and protein degradation tags, can be used to tune gene expression and characteristics of the CRISPRi/a tool (Depardieu and Bikard, 2020; Fleck and Grundner, 2021; Ouellette et al., 2021). However, the components cannot be expressed so low that it cannot effectively repress or activate the target gene(s), especially during multiplexed gene regulation that relies on a shared dCas protein pool for multiple gRNAs (Zhang and Voigt, 2018; Zhao et al., 2018). A careful balance is required to express the CRISPRi/a components.

Current CRISPRi/a Tools for Non-Model Bacteria

Different CRISPRi/a tools have been established in a range of bacteria that span many phyla and have been used for a variety of applications, as summarized below (Table 1). Overwhelmingly, these studies have utilized the Sp dCas9 CRISPRi system. A key for the study indices and more detailed information for each study can be found in Table S1.

Actinomycetota

CRISPRi has been well established in a wide range of Actinobacteria, including *Mycobacteria*, *Streptomyces*, and *Corynebacterium*, and has been used for metabolic engineering and the elucidation of gene functions in both small studies and genome-wide screens (Table 1). Additionally, several CRISPRi tools are commonly used in *Mycobacteria* (Choudhary et al., 2015; Rock et al., 2017; Agarwal, 2020; Fleck and Grundner, 2021) and *Streptomyces* (Tong et al., 2015; Li et al., 2018; Zhao et al., 2018). CRISPRa has also been recently established in *Corynebacterium* (Liu et al., 2019a) and *Streptomyces* (Ameruso et al., 2021).

Cyanobacteria

CRISPRi/a is especially useful in cyanobacteria due to their polyploid genomes (Kirtania et al., 2019). CRISPRi is relatively well-established in a wide range of cyanobacterial species, including those of research and industrial significance, and has been used for metabolic engineering, transcriptional regulatory networks, and the study of gene functions in small studies and a genome-wide screen/selection (Table 1). Many CRISPRi tools are available in cyanobacteria, each with their own characteristics (Gordon et al., 2016; Yao et al., 2016; Choi and Woo, 2020; Liu et al., 2020a). CRISPRa has not yet been reported in cyanobacteria.

Firmicutes

CRISPRi is well-established in a wide range of Firmicutes, including *Bacilli*, *Clostridia*, *Staphylococci*, and *Streptococci* (Table 1). CRISPRi tools have been developed and used for metabolic engineering, elucidation of gene functions, and genome-wide screens and selections.

CRISPRa has been reported in *Bacillus amyloliquefaciens* and *Paenibacillus polymyxa* in tool development work and some metabolic engineering applications (Schilling et al., 2020; Zhao et al., 2020).

Proteobacteria

CRISPRi and CRISPRa are well established in a wide variety of Proteobacteria, including *Klebsiella*, *Salmonella*, *Pseudomonas*, and *Vibrio* (Table 1). These tools have been developed and used for metabolic engineering, synthetic transcriptional regulatory networks, and mapping gene function using small gRNA sets and genome-wide screens and selections. Reports of CRISPRi are far more common than CRISPRa.

Other Bacterial Phyla

CRISPRi has also been reported in the phyla Chlamydiae, Tenericutes, Spirochaetes, and Bacteroidetes (Table 1). Although these reports have primarily been for tool development, some have used CRISPRi to investigate gene function (Brockett et al., 2021; Fernandes et al., 2021b) or create synthetic genetic circuits (Mimee et al., 2015; Taketani et al., 2020).

Applications of CRISPRi/a in Non-Model Bacteria

CRISPRi/a tools can be used for a variety of applications in non-model bacteria (Fig 1). The most common application is mapping a gene's function by altering its gene expression and assaying cellular phenotypic change under some applied selective condition (Fig 1A). CRISPRi is particularly useful for investigating essential genes because its repression can be titrated to prevent full knockdown and cell death (Knoot et al., 2020; Bosch et al., 2021). Additionally, epistatic effects of multiple genes can easily be investigated by simply expressing multiple gRNA within the same cell (Ellis et al., 2021; McNeil et al., 2022). Although not as common as CRISPRi due to stricter design rules (Fontana et al., 2020a), CRISPRa can be used to induce expression of silent genes to investigate their functions and products, including entire silent biosynthetic gene clusters (Ke et al., 2021). Combined, these are the most common use of CRISPRi/a tools in non-model bacteria, with 80 reports across six phyla (Table 1) (Behler et al., 2018; Stamsås et al., 2018; Ke et al., 2021). The recent development of Mobile-CRISPRi (Peters et al., 2019), CRAGE-CRISPR (Ke et al., 2021), and a workflow for introducing genetic manipulation tools into non-model gut bacteria (Jin et al., 2022) will facilitate the expansion of CRISPRi/a tools into new species and strains, including recalcitrant pathogens and novel species without sequenced genomes.

Additionally, CRISPRi/a can be used to control transcription regulatory networks, such as genetic circuits, by designing and expressing gRNA to regulate the output promoter for each logic gate or node (Fig 1B). CRISPRi/a is especially effective for controlling complex synthetic transcription regulatory networks as the gRNA can be designed to target nearly any arbitrary sequence with an appropriate PAM (or equivalent) sequence (Taketani et al., 2020; Ellis et al., 2021). CRISPRi/a circuits can be fully synthetic and auxiliary to the native genetic regulatory networks, such as a heterologous sensor or multi-input circuit that senses and responds to external inputs in complex environments (Mimee et al., 2015; Taketani et al., 2020). Alternatively, CRISPRi/a can be interfaced with native gene regulatory systems to control the host's metabolism in response to external stimuli, such as cell density, through either heterologous (Liu et al., 2020b) or even indigenous sensor systems (Tian et al., 2020). However, caution must be taken to prevent the expression of too many gRNA at once since they compete over the limited dCas protein resource and, thus, can decrease the repression of target genes (Del Vecchio et al., 2008; Li et al., 2018; Zhang and Voigt, 2018).

Synthetic CRISPRi/a regulatory networks are rare in non-model bacteria, having been reported in only seven studies across four phyla, and primarily incorporate CRISPRi (Table 1). However, a single CRISPRa genetic circuit in *Salmonella* has been reported (Bhokisham et al., 2020).

CRISPRi/a tools have also been used to redirect carbon and energy flow for metabolic engineering in non-model bacteria (Fig 3C). CRISPRi is often used to repress a native gene(s), including essential genes, to redirect carbon flux towards a desired product (Wang et al., 2017; Shabestary et al., 2018) or bioactive molecule (Yu et al., 2018; Liu et al., 2021b). CRISPRa can be used to activate the desired metabolic pathway to increase biosynthesis of the desired product, such as an anti-cancer drug in a weakly-expressed biosynthetic gene cluster (Peng et al., 2018; Ye et al., 2019). In most examples, the CRISPRi/a components are constitutively expressed, yet some studies employ dynamic metabolic engineering strategies by utilizing inducible systems and/or genetically encoded biosensors to switch between cell growth and product biosynthesis states to improve production (Liu et al., 2020b; Tian et al., 2020; Shabestary et al., 2021). These tools can be used to tune endogenous metabolism and/or heterologous metabolic pathways (Peng et al., 2018; Banerjee et al., 2020). CRISPRi/a tools are most often combined with other metabolic engineering techniques, such as the deletion, overexpression, or mutation of select genes and optimization of medium, to further increase titers of the desired product (Park et al., 2019; Dietsch et al., 2021; Kozaeva et al., 2021).

Large-scale CRISPRi screens and selections have been developed to investigate genotype-phenotype relationships through gRNA fitness (Fig 1D). These assays can use small, targeted libraries, such as essential genes or genes in a metabolic pathway (Shields et al., 2020; Göttl et al., 2021), or large genome-wide libraries targeting nearly all genes in the bacterial genome (Lee et al., 2019; Jiang et al., 2020). Additionally, CRISPRi libraries can be constructed in two major forms – pooled libraries, where cells containing different gRNA are mixed during library construction (Bosch et al., 2021; Rahman et al., 2021), a strategy known as multiplexing, or arrayed libraries where different gRNA designs are constructed individually in different clonal populations, typically arrayed in microtiter plates (Liu et al., 2017; Göttl et al., 2021). Pooled competitive selections are more common due to the ease of DNA construction and analysis of large, genome-scale gRNA libraries with >10,000 designs by next-generation sequencing (Lee et al., 2019; Bosch et al., 2021). However, because all cells directly compete in pooled competitive growth assays, “cheaters” may arise that take advantage of different strain interactions, so the results of any individual gRNA design should be verified in isolation (Yao et al., 2020; Liu et al., 2021a). Additionally, the results from these pooled CRISPRi screens or selections are specific to the gRNA design and not the target gene since confounding effects (i.e., off-target effects) could produce false positives or negatives, so careful design of gRNA libraries is vital (Cui et al., 2018; Wang et al., 2018b). Genome-wide CRISPRi screens or selections are relatively uncommon (Table 1). While not demonstrated to date, genome-wide bacterial CRISPRa is theoretically possible, provided the design rules for activation are met (Fontana et al., 2020a).

Conclusions and Perspectives

CRISPRi has been established in non-model bacteria across eight phyla and applied from small, single gene functional studies to large genome-wide screens. The creation of new tools and protocols for introducing CRISPRi/a into non-model bacteria will facilitate the continuation of this rapid expansion. Several novel and exciting CRISPRa tools with greater activation and unique characteristics have been developed recently in both model and non-model bacteria, yet there remains

a need for stronger and more versatile bacterial CRISPRa tools, especially for the activation of native genes. These bacterial CRISPRa tools have lagged behind the development of both eukaryotic CRISPRa tools and bacterial CRISPRi tools. However, the recent development of several new CRISPRa systems with less stringent design rules and higher levels of activation (>10-fold) shows great promise for effective, tailored gene activation in bacteria (Liu et al., 2019b; Fontana et al., 2020a; Ho et al., 2020; Villegas Kcam et al., 2021). These CRISPRa technologies were created using directed evolution and thorough tool design. Further improvements could be achieved by creating CRISPRa tools from CRISPR systems with more relaxed PAM requirements, directed evolution of CRISPRa components (activator domain, gRNA scaffold(s), and dCas protein) for greater activation, and high-throughput screening of gRNAs and promoters to uncover additional nuanced design rules for a given tool. CRISPRa has the potential to become a more effective and widely used tool for programmable gene activation in both model and non-model bacteria for a variety of industrial and research applications, such as metabolic engineering and elucidation of gene function. While many CRISPRi/a approaches in non-model bacteria have been established using genetic parts that are not well-defined or characterized, the creation of comprehensive genetic part toolboxes for these strains, which are vital for the rational design and precise control of CRISPRi/a tools, will accelerate further development and optimization of the tools. Finally, CRISPRi/a approaches have primarily been developed for more genetically tractable strains of non-model bacteria. There is a need for efficient workflows to domesticate and introduce CRISPRi/a tools to novel bacterial species. Despite these current challenges, CRISPRi/a technology remains a versatile approach for programmable transcriptional regulation in non-model bacteria.

2 Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

3 Author Contributions

SC and LA conceived of the review and wrote the manuscript. All authors read and approved the manuscript.

4 Funding

This material is based upon work supported by the National Science Foundation under Grant No. DMR-1904901 to LBA. Additional funding for this work was provided by startup funds to LBA from the University of Massachusetts Amherst and a seed grant award from the UMass ADVANCE program funded by the National Science Foundation (awards #1824090 & #2136150). This work is also supported by the National Science Foundation Graduate Research Fellowship under Grant No. DGE- 1451512 to SNC.

5 Acknowledgments

The authors would like to thank members of the Andrews research group for their discussions contributing to the manuscript.

6 References

- Afonina, I., Ong, J., Chua, J., Lu, T., and Kline, K. A. (2020). Multiplex CRISPRi System Enables the Study of Stage-Specific Biofilm Genetic Requirements in *Enterococcus faecalis*. *mBio*. doi:10.1128/mBio.01101-20.
- Agarwal, N. (2020). Construction of a novel CRISPRi-based tool for silencing of multiple genes in *Mycobacterium tuberculosis*. *Plasmid* 110, 102515. doi:10.1016/j.plasmid.2020.102515.
- Ameruoso, A., Kcam, M. C. V., Cohen, K. P., and Chappell, J. (2021). Activating natural product synthesis using CRISPR interference and activation systems in *Streptomyces*. 2021.10.28.466254. doi:10.1101/2021.10.28.466254.
- Bai, J., Dai, Y., Farinha, A., Tang, A. Y., Syal, S., Vargas-Cuebas, G., et al. (2021). Essential Gene Analysis in *Acinetobacter baumannii* by High-Density Transposon Mutagenesis and CRISPR Interference. *Journal of Bacteriology*. doi:10.1128/JB.00565-20.
- Banerjee, D., Eng, T., Lau, A. K., Sasaki, Y., Wang, B., Chen, Y., et al. (2020). Genome-scale metabolic rewiring improves titers rates and yields of the non-native product indigoidine at scale. *Nat Commun* 11, 5385. doi:10.1038/s41467-020-19171-4.
- Banta, A. B., Enright, A. L., Siletti, C., and Peters, J. M. (2020). A High-Efficacy CRISPR Interference System for Gene Function Discovery in *Zymomonas mobilis*. *Applied and Environmental Microbiology*. doi:10.1128/AEM.01621-20.
- Baranowski, C., Welsh, M. A., Sham, L.-T., Eskandarian, H. A., Lim, H. C., Kieser, K. J., et al. (2018). Maturing *Mycobacterium smegmatis* peptidoglycan requires non-canonical crosslinks to maintain shape. *eLife* 7, e37516. doi:10.7554/eLife.37516.
- Batianis, C., Kozaeva, E., Damalas, S. G., Martín-Pascual, M., Volke, D. C., Nikel, P. I., et al. (2020). An expanded CRISPRi toolbox for tunable control of gene expression in *Pseudomonas putida*. *Microbial Biotechnology* 13, 368–385. doi:10.1111/1751-7915.13533.
- Behle, A., Dietsch, M., Goldschmidt, L., Murugathas, W., Brandt, D., Busche, T., et al. (2021). Uncoupling of the Diurnal Growth Program by Artificial Genome Relaxation in *Synechocystis* sp. PCC 6803. 2021.07.26.453758. doi:10.1101/2021.07.26.453758.
- Behler, J., Sharma, K., Reimann, V., Wilde, A., Urlaub, H., and Hess, W. R. (2018). The host-encoded RNase E endonuclease as the crRNA maturation enzyme in a CRISPR–Cas subtype III-Bv system. *Nat Microbiol* 3, 367–377. doi:10.1038/s41564-017-0103-5.
- Berlec, A., Škrlec, K., Kocjan, J., Olenic, M., and Štrukelj, B. (2018). Single plasmid systems for inducible dual protein expression and for CRISPR-Cas9/CRISPRi gene regulation in lactic acid bacterium *Lactococcus lactis*. *Sci Rep* 8, 1009. doi:10.1038/s41598-018-19402-1.
- Bhokisham, N., VanArsdale, E., Stephens, K. T., Hauk, P., Payne, G. F., and Bentley, W. E. (2020). A redox-based electrogenetic CRISPR system to connect with and control biological information networks. *Nat Commun* 11, 2427. doi:10.1038/s41467-020-16249-x.

- 377 Bikard, D., Jiang, W., Samai, P., Hochschild, A., Zhang, F., and Marraffini, L. A. (2013).
378 Programmable repression and activation of bacterial gene expression using an engineered
379 CRISPR-Cas system. *Nucleic Acids Research* 41, 7429–7437. doi:10.1093/nar/gkt520.
- 380 Bosch, B., DeJesus, M. A., Poulton, N. C., Zhang, W., Engelhart, C. A., Zaveri, A., et al. (2021).
381 Genome-wide gene expression tuning reveals diverse vulnerabilities of *M. tuberculosis*. *Cell* 184,
382 4579–4592.e24. doi:10.1016/j.cell.2021.06.033.
- 383 Brito, L. F., Schultenkämper, K., Passaglia, L. M. P., and Wendisch, V. F. (2020). CRISPR
384 interference-based gene repression in the plant growth promoter *Paenibacillus sonchi* genomovar
385 *Riograndensis* SBR5. *Appl Microbiol Biotechnol* 104, 5095–5106. doi:10.1007/s00253-020-
386 10571-6.
- 387 Brockett, M. R., Lee, J., Cox, J. V., Liechti, G. W., and Ouellette, S. P. (2021). A Dynamic, Ring-
388 Forming Bactofilin Critical for Maintaining Cell Size in the Obligate Intracellular Bacterium
389 *Chlamydia trachomatis*. *Infection and Immunity*. doi:10.1128/IAI.00203-21.
- 390 Bruder, M. R., Pyne, M. E., Moo-Young, M., Chung, D. A., and Chou, C. P. (2016). Extending
391 CRISPR-Cas9 Technology from Genome Editing to Transcriptional Engineering in the Genus
392 *Clostridium*. *Applied and Environmental Microbiology*. doi:10.1128/AEM.02128-16.
- 393 Brzostek, A., Płociński, P., Minias, A., Ciszewska, A., Gąsior, F., Pawełczyk, J., et al. (2021).
394 Dissecting the RecA-(In)dependent Response to Mitomycin C in *Mycobacterium tuberculosis*
395 Using Transcriptional Profiling and Proteomics Analyses. *Cells* 10, 1168.
396 doi:10.3390/cells10051168.
- 397 Cao, Y., Li, X., Li, F., and Song, H. (2017). CRISPRi-sRNA: Transcriptional–Translational
398 Regulation of Extracellular Electron Transfer in *Shewanella oneidensis*. *ACS Synth. Biol.* 6,
399 1679–1690. doi:10.1021/acssynbio.6b00374.
- 400 Caro, F., Place, N. M., and Mekalanos, J. J. (2019). Analysis of lipoprotein transport depletion in
401 *Vibrio cholerae* using CRISPRi. *PNAS* 116, 17013–17022. doi:10.1073/pnas.1906158116.
- 402 Chai, G., Yu, M., Jiang, L., Duan, Y., and Huang, J. (2019). HMMCAS: A Web Tool for the
403 Identification and Domain Annotations of CAS Proteins. *IEEE/ACM Transactions on*
404 *Computational Biology and Bioinformatics* 16, 1313–1315. doi:10.1109/TCBB.2017.2665542.
- 405 Chen, W., Zhang, Y., Yeo, W.-S., Bae, T., and Ji, Q. (2017). Rapid and Efficient Genome Editing in
406 *Staphylococcus aureus* by Using an Engineered CRISPR/Cas9 System. *J. Am. Chem. Soc.* 139,
407 3790–3795. doi:10.1021/jacs.6b13317.
- 408 Cheung, C.-Y., McNeil, M. B., and Cook, G. M. (2021). Utilization of CRISPR interference to
409 investigate the contribution of genes to pathogenesis in a macrophage model of *Mycobacterium*
410 *tuberculosis* infection. *Journal of Antimicrobial Chemotherapy*, dkab437.
411 doi:10.1093/jac/dkab437.
- 412 Cho, S., Choe, D., Lee, E., Kim, S. C., Palsson, B., and Cho, B.-K. (2018). High-Level dCas9
413 Expression Induces Abnormal Cell Morphology in *Escherichia coli*. *ACS Synth. Biol.* 7, 1085–
414 1094. doi:10.1021/acssynbio.7b00462.

- 415 Choi, S. Y., and Woo, H. M. (2020). CRISPRi-dCas12a: A dCas12a-Mediated CRISPR Interference
416 for Repression of Multiple Genes and Metabolic Engineering in Cyanobacteria. *ACS Synth. Biol.*
417 9, 2351–2361. doi:10.1021/acssynbio.0c00091.
- 418 Choudhary, E., Sharma, R., Kumar, Y., and Agarwal, N. (2019). Conditional Silencing by CRISPRi
419 Reveals the Role of DNA Gyrase in Formation of Drug-Tolerant Persister Population in
420 *Mycobacterium tuberculosis*. *Frontiers in Cellular and Infection Microbiology* 9. Available at:
421 <https://www.frontiersin.org/article/10.3389/fcimb.2019.00070> [Accessed January 25, 2022].
- 422 Choudhary, E., Thakur, P., Pareek, M., and Agarwal, N. (2015). Gene silencing by CRISPR
423 interference in mycobacteria. *Nat Commun* 6, 6267. doi:10.1038/ncomms7267.
- 424 Cleto, S., Jensen, J. V., Wendisch, V. F., and Lu, T. K. (2016). *Corynebacterium glutamicum*
425 Metabolic Engineering with CRISPR Interference (CRISPRi). *ACS Synth. Biol.* 5, 375–385.
426 doi:10.1021/acssynbio.5b00216.
- 427 Colquhoun, J. M., Farokhyfar, M., Hutcheson, A. R., Anderson, A., Bethel, C. R., Bonomo, R. A., et
428 al. (2021). OXA-23 β -Lactamase Overexpression in *Acinetobacter baumannii* Drives
429 Physiological Changes Resulting in New Genetic Vulnerabilities. *mBio*.
430 doi:10.1128/mBio.03137-21.
- 431 Couvin, D., Bernheim, A., Toffano-Nioche, C., Touchon, M., Michalik, J., Néron, B., et al. (2018).
432 CRISPRCasFinder, an update of CRISRFinder, includes a portable version, enhanced
433 performance and integrates search for Cas proteins. *Nucleic Acids Research* 46, W246–W251.
434 doi:10.1093/nar/gky425.
- 435 Cui, L., Vigouroux, A., Rousset, F., Varet, H., Khanna, V., and Bikard, D. (2018). A CRISPRi screen
436 in *E. coli* reveals sequence-specific toxicity of dCas9. *Nat Commun* 9, 1912. doi:10.1038/s41467-
437 018-04209-5.
- 438 Czajka, J. J., Banerjee, D., Eng, T., Menasalvas, J., Yan, C., Munoz, N. M., et al. (2021). Optimizing
439 a High Performing Multiplex-CRISPRi *P. putida* Strain with Integrated Metabolomics and ¹³C-
440 Metabolic Flux Analyses. 2021.12.23.473729. doi:10.1101/2021.12.23.473729.
- 441 Dai, Y., Pinedo, V., Tang, A. Y., Cava, F., and Geisinger, E. (2021). A New Class of Cell Wall-
442 Recycling L,d-Carboxypeptidase Determines β -Lactam Susceptibility and Morphogenesis in
443 *Acinetobacter baumannii*. *mBio*. doi:10.1128/mBio.02786-21.
- 444 Dammann, A. N., Chamby, A. B., Catomeris, A. J., Davidson, K. M., Tettelin, H., Pijkeren, J.-P. van,
445 et al. (2021). Genome-Wide fitness analysis of group B *Streptococcus* in human amniotic fluid
446 reveals a transcription factor that controls multiple virulence traits. *PLOS Pathogens* 17,
447 e1009116. doi:10.1371/journal.ppat.1009116.
- 448 de Bakker, V., Liu, X., Bravo, A. M., and Veening, J.-W. (2022). CRISPRi-seq for genome-wide
449 fitness quantification in bacteria. *Nat Protoc*, 1–30. doi:10.1038/s41596-021-00639-6.
- 450 de Wet, T. J., Winkler, K. R., Mhlanga, M., Mizrahi, V., and Warner, D. F. (2020). Arrayed
451 CRISPRi and quantitative imaging describe the morphotypic landscape of essential mycobacterial
452 genes. *eLife* 9, e60083. doi:10.7554/eLife.60083.

- 453 Del Vecchio, D., Ninfa, A., and Sontag, E. (2008). Modular cell biology: retroactivity and insulation.
454 *Molecular Systems Biology* 4, 161. doi:10.1038/msb4100204.
- 455 DeLorenzo, D. M., Diao, J., Carr, R., Hu, Y., and Moon, T. S. (2021). An Improved CRISPR
456 Interference Tool to Engineer *Rhodococcus opacus*. *ACS Synth. Biol.* 10, 786–798.
457 doi:10.1021/acssynbio.0c00591.
- 458 DeLorenzo, D. M., Rottinghaus, A. G., Henson, W. R., and Moon, T. S. (2018). Molecular Toolkit
459 for Gene Expression Control and Genome Modification in *Rhodococcus opacus* PD630. *ACS*
460 *Synth. Biol.* 7, 727–738. doi:10.1021/acssynbio.7b00416.
- 461 Depardieu, F., and Bikard, D. (2020). Gene silencing with CRISPRi in bacteria and optimization of
462 dCas9 expression levels. *Methods* 172, 61–75. doi:10.1016/j.ymeth.2019.07.024.
- 463 Dewachter, L., Liu, X., Dénéréaz, J., Bakker, V. de, Costa, C., Baldry, M., et al. (2021). Amoxicillin-
464 resistant *Streptococcus pneumoniae* can be resensitized by targeting the mevalonate pathway as
465 indicated by sCRilecs-seq. 2021.09.13.460059. doi:10.1101/2021.09.13.460059.
- 466 Dietsch, M., Behle, A., Westhoff, P., and Axmann, I. M. (2021). Metabolic engineering of
467 *Synechocystis* sp. PCC 6803 for the photoproduction of the sesquiterpene valencene. *Metabolic*
468 *Engineering Communications* 13, e00178. doi:10.1016/j.mec.2021.e00178.
- 469 Domenech, A., Slager, J., and Veening, J.-W. (2018). Antibiotic-Induced Cell Chaining Triggers
470 Pneumococcal Competence by Reshaping Quorum Sensing to Autocrine-Like Signaling. *Cell*
471 *Reports* 25, 2390–2400.e3. doi:10.1016/j.celrep.2018.11.007.
- 472 Dong, C., Fontana, J., Patel, A., Carothers, J. M., and Zalatan, J. G. (2018). Synthetic CRISPR-Cas
473 gene activators for transcriptional reprogramming in bacteria. *Nat Commun* 9, 2489.
474 doi:10.1038/s41467-018-04901-6.
- 475 Dong, X., Jin, Y., Ming, D., Li, B., Dong, H., Wang, L., et al. (2017). CRISPR/dCas9-mediated
476 inhibition of gene expression in *Staphylococcus aureus*. *Journal of Microbiological Methods* 139,
477 79–86. doi:10.1016/j.mimet.2017.05.008.
- 478 Dutta, A. K., Choudhary, E., Wang, X., Záhorszka, M., Forbak, M., Lohner, P., et al. (2019).
479 Trehalose Conjugation Enhances Toxicity of Photosensitizers against *Mycobacteria*. *ACS Cent.*
480 *Sci.* 5, 644–650. doi:10.1021/acscentsci.8b00962.
- 481 Ellis, N. A., Kim, B., Tung, J., and Machner, M. P. (2021). A multiplex CRISPR interference tool for
482 virulence gene interrogation in *Legionella pneumophila*. *Commun Biol* 4, 1–13.
483 doi:10.1038/s42003-021-01672-7.
- 484 Fackler, N., Heffernan, J., Juminaga, A., Doser, D., Nagaraju, S., Gonzalez-Garcia, R. A., et al.
485 (2021). Transcriptional control of *Clostridium autoethanogenum* using CRISPRi. *Synthetic*
486 *Biology* 6, ysab008. doi:10.1093/synbio/ysab008.
- 487 Faulkner, V., Cox, A. A., Goh, S., van Bohemen, A., Gibson, A. J., Liebster, O., et al. (2021). Re-
488 sensitization of *Mycobacterium smegmatis* to Rifampicin Using CRISPR Interference
489 Demonstrates Its Utility for the Study of Non-essential Drug Resistance Traits. *Frontiers in*

- 490 *Microbiology* 11. Available at: <https://www.frontiersin.org/article/10.3389/fmicb.2020.619427>
491 [Accessed February 5, 2022].
- 492 Fernandes, L. G. V., Guaman, L. P., Vasconcellos, S. A., Heinemann, M. B., Picardeau, M., and
493 Nascimento, A. L. T. O. (2019). Gene silencing based on RNA-guided catalytically inactive Cas9
494 (dCas9): a new tool for genetic engineering in *Leptospira*. *Sci Rep* 9, 1839. doi:10.1038/s41598-
495 018-37949-x.
- 496 Fernandes, L. G. V., Hornsby, R. L., Nascimento, A. L. T. O., and Nally, J. E. (2021a). Application
497 of CRISPR Interference (CRISPRi) for Gene Silencing in Pathogenic Species of *Leptospira*.
498 *JoVE (Journal of Visualized Experiments)*, e62631. doi:10.3791/62631.
- 499 Fernandes, L. G. V., Hornsby, R. L., Nascimento, A. L. T. O., and Nally, J. E. (2021b). Genetic
500 manipulation of pathogenic *Leptospira*: CRISPR interference (CRISPRi)-mediated gene silencing
501 and rapid mutant recovery at 37 °C. *Sci Rep* 11, 1768. doi:10.1038/s41598-021-81400-7.
- 502 Fleck, N., and Grundner, C. (2021). A Cas12a-based CRISPR interference system for multigene
503 regulation in mycobacteria. *Journal of Biological Chemistry* 297. doi:10.1016/j.jbc.2021.100990.
- 504 Fonfara, I., Richter, H., Bratovič, M., Le Rhun, A., and Charpentier, E. (2016). The CRISPR-
505 associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA. *Nature* 532,
506 517–521. doi:10.1038/nature17945.
- 507 Fontana, J., Dong, C., Kiattisewee, C., Chavali, V. P., Tickman, B. I., Carothers, J. M., et al. (2020a).
508 Effective CRISPRa-mediated control of gene expression in bacteria must overcome strict target
509 site requirements. *Nat Commun* 11, 1618. doi:10.1038/s41467-020-15454-y.
- 510 Fontana, J., Sparkman-Yager, D., Zalatan, J. G., and Carothers, J. M. (2020b). Challenges and
511 opportunities with CRISPR activation in bacteria for data-driven metabolic engineering. *Current*
512 *Opinion in Biotechnology* 64, 190–198. doi:10.1016/j.copbio.2020.04.005.
- 513 Gallay, C., Sanselicio, S., Anderson, M. E., Soh, Y. M., Liu, X., Stamsås, G. A., et al. (2021). CcrZ is
514 a pneumococcal spatiotemporal cell cycle regulator that interacts with FtsZ and controls DNA
515 replication by modulating the activity of DnaA. *Nat Microbiol* 6, 1175–1187.
516 doi:10.1038/s41564-021-00949-1.
- 517 Ganguly, J., Martin-Pascual, M., and van Kranenburg, R. (2020). CRISPR interference (CRISPRi) as
518 transcriptional repression tool for *Hungateiclostridium thermocellum* DSM 1313. *Microbial*
519 *Biotechnology* 13, 339–349. doi:10.1111/1751-7915.13516.
- 520 Gani, Z., Boradia, V. M., Kumar, A., Patidar, A., Talukdar, S., Choudhary, E., et al. (2021).
521 *Mycobacterium tuberculosis* glyceraldehyde-3-phosphate dehydrogenase plays a dual role—As
522 an adhesin and as a receptor for plasmin(ogen). *Cellular Microbiology* 23, e13311.
523 doi:10.1111/cmi.13311.
- 524 Gauttam, R., Mukhopadhyay, A., Simmons, B. A., and Singer, S. W. (2021). Development of dual-
525 inducible duet-expression vectors for tunable gene expression control and CRISPR interference-
526 based gene repression in *Pseudomonas putida* KT2440. *Microbial Biotechnology* 14, 2659–2678.
527 doi:10.1111/1751-7915.13832.

- 528 Gauttam, R., Seibold, G. M., Mueller, P., Weil, T., Weiß, T., Handrick, R., et al. (2019). A simple
529 dual-inducible CRISPR interference system for multiple gene targeting in *Corynebacterium*
530 *glutamicum*. *Plasmid* 103, 25–35. doi:10.1016/j.plasmid.2019.04.001.
- 531 Gelin, M., Paoletti, J., Nahori, M.-A., Huteau, V., Leseigneur, C., Jouvion, G., et al. (2020). From
532 Substrate to Fragments to Inhibitor Active In Vivo against *Staphylococcus aureus*. *ACS Infect.*
533 *Dis.* 6, 422–435. doi:10.1021/acsinfecdis.9b00368.
- 534 Geng, P., Leonard, S. P., Mishler, D. M., and Barrick, J. E. (2019). Synthetic Genome Defenses
535 against Selfish DNA Elements Stabilize Engineered Bacteria against Evolutionary Failure. *ACS*
536 *Synth. Biol.* 8, 521–531. doi:10.1021/acssynbio.8b00426.
- 537 Gibson, A. J., Passmore, I. J., Faulkner, V., Xia, D., Nobeli, I., Stiens, J., et al. (2021). Probing
538 Differences in Gene Essentiality Between the Human and Animal Adapted Lineages of the
539 *Mycobacterium tuberculosis* Complex Using TnSeq. *Frontiers in Veterinary Science* 8. Available
540 at: <https://www.frontiersin.org/article/10.3389/fvets.2021.760717> [Accessed February 2, 2022].
- 541 Gordon, G. C., Korosh, T. C., Cameron, J. C., Markley, A. L., Begemann, M. B., and Pfleger, B. F.
542 (2016). CRISPR interference as a titratable, trans-acting regulatory tool for metabolic engineering
543 in the cyanobacterium *Synechococcus* sp. strain PCC 7002. *Metabolic Engineering* 38, 170–179.
544 doi:10.1016/j.ymben.2016.07.007.
- 545 Göttl, V. L., Schmitt, I., Braun, K., Peters-Wendisch, P., Wendisch, V. F., and Henke, N. A. (2021).
546 CRISPRi-Library-Guided Target Identification for Engineering Carotenoid Production by
547 *Corynebacterium glutamicum*. *Microorganisms* 9, 670. doi:10.3390/microorganisms9040670.
- 548 Guzzo, M., Castro, L. K., Reisch, C. R., Guo, M. S., and Laub, M. T. (2020). A CRISPR Interference
549 System for Efficient and Rapid Gene Knockdown in *Caulobacter crescentus*. *mBio*.
550 doi:10.1128/mBio.02415-19.
- 551 Higo, A., and Ehira, S. (2019). Spatiotemporal Gene Repression System in the Heterocyst-Forming
552 Multicellular Cyanobacterium *Anabaena* sp. PCC 7120. *ACS Synth. Biol.* 8, 641–646.
553 doi:10.1021/acssynbio.8b00496.
- 554 Higo, A., Isu, A., Fukaya, Y., Ehira, S., and Hisabori, T. (2018). Application of CRISPR Interference
555 for Metabolic Engineering of the Heterocyst-Forming Multicellular Cyanobacterium *Anabaena*
556 sp. PCC 7120. *Plant and Cell Physiology* 59, 119–127. doi:10.1093/pcp/pcx166.
- 557 Higo, A., Nishiyama, E., Nakamura, K., Hihara, Y., and Ehira, S. (2019). cyAbrB Transcriptional
558 Regulators as Safety Devices To Inhibit Heterocyst Differentiation in *Anabaena* sp. Strain PCC
559 7120. *Journal of Bacteriology*. doi:10.1128/JB.00244-19.
- 560 Ho, H.-I., Fang, J., Cheung, J., and Wang, H. (2020). Programmable CRISPR-Cas transcriptional
561 activation in bacteria. *Molecular Systems Biology* 16, e9427. doi:10.15252/msb.20199427.
- 562 Hogan, A. M., Rahman, A. S. M. Z., Lightly, T. J., and Cardona, S. T. (2019). A Broad-Host-Range
563 CRISPRi Toolkit for Silencing Gene Expression in *Burkholderia*. *ACS Synth. Biol.* 8, 2372–2384.
564 doi:10.1021/acssynbio.9b00232.

- 565 Huang, C.-H., Shen, C. R., Li, H., Sung, L.-Y., Wu, M.-Y., and Hu, Y.-C. (2016). CRISPR
566 interference (CRISPRi) for gene regulation and succinate production in cyanobacterium *S.*
567 *elongatus* PCC 7942. *Microbial Cell Factories* 15, 196. doi:10.1186/s12934-016-0595-3.
- 568 Huang, J., Chen, J., Wang, Y., Shi, T., Ni, X., Pu, W., et al. (2021). Development of a Hyperosmotic
569 Stress Inducible Gene Expression System by Engineering the MtrA/MtrB-Dependent NCgl1418
570 Promoter in *Corynebacterium glutamicum*. *Frontiers in Microbiology* 12. Available at:
571 <https://www.frontiersin.org/article/10.3389/fmicb.2021.718511> [Accessed February 14, 2022].
- 572 Huang, L.-H., Liu, Q.-J., Sun, X.-W., Li, X.-J., Liu, M., Jia, S.-R., et al. (2020). Tailoring bacterial
573 cellulose structure through CRISPR interference-mediated downregulation of *galU* in
574 *Komagataeibacter xylinus* CGMCC 2955. *Biotechnology and Bioengineering* 117, 2165–2176.
575 doi:10.1002/bit.27351.
- 576 Irnov, I., Wang, Z., Jannetty, N. D., Bustamante, J. A., Rhee, K. Y., and Jacobs-Wagner, C. (2017).
577 Crosstalk between the tricarboxylic acid cycle and peptidoglycan synthesis in *Caulobacter*
578 *crescentus* through the homeostatic control of α -ketoglutarate. *PLOS Genetics* 13, e1006978.
579 doi:10.1371/journal.pgen.1006978.
- 580 Jackson, S. A., McKenzie, R. E., Fagerlund, R. D., Kieper, S. N., Fineran, P. C., and Brouns, S. J. J.
581 (2017). CRISPR-Cas: Adapting to change. *Science* 356, eaal5056. doi:10.1126/science.aal5056.
- 582 Jiang, F., Zhou, K., Ma, L., Gressel, S., and Doudna, J. A. (2015). A Cas9–guide RNA complex
583 preorganized for target DNA recognition. *Science*. doi:10.1126/science.aab1452.
- 584 Jiang, W., Oikonomou, P., and Tavazoie, S. (2020). Comprehensive Genome-wide Perturbations via
585 CRISPR Adaptation Reveal Complex Genetics of Antibiotic Sensitivity. *Cell* 180, 1002-
586 1017.e31. doi:10.1016/j.cell.2020.02.007.
- 587 Jin, W.-B., Li, T.-T., Huo, D., Qu, S., Li, X. V., Arifuzzaman, M., et al. (2022). Genetic manipulation
588 of gut microbes enables single-gene interrogation in a complex microbiome. *Cell* 185, 547-
589 562.e22. doi:10.1016/j.cell.2021.12.035.
- 590 Judd, J. A., Canestrari, J., Clark, R., Joseph, A., Lapierre, P., Lasek-Nesselquist, E., et al. (2021). A
591 Mycobacterial Systems Resource for the Research Community. *mBio*. doi:10.1128/mBio.02401-
592 20.
- 593 Kaczmarzyk, D., Cengic, I., Yao, L., and Hudson, E. P. (2018). Diversion of the long-chain acyl-
594 ACP pool in *Synechocystis* to fatty alcohols through CRISPRi repression of the essential
595 phosphate acyltransferase *PlsX*. *Metabolic Engineering* 45, 59–66.
596 doi:10.1016/j.ymben.2017.11.014.
- 597 Kampmann, M. (2018). CRISPRi and CRISPRa Screens in Mammalian Cells for Precision Biology
598 and Medicine. *ACS Chem. Biol.* 13, 406–416. doi:10.1021/acscchembio.7b00657.
- 599 Ke, J., Robinson, D., Wu, Z.-Y., Kuftin, A., Louie, K., Kosina, S., et al. (2021). CRAGE-CRISPR
600 facilitates rapid activation of secondary metabolite biosynthetic gene clusters in bacteria. *Cell*
601 *Chemical Biology*. doi:10.1016/j.chembiol.2021.08.009.

- 602 Kiattisewee, C., Dong, C., Fontana, J., Sugianto, W., Peralta-Yahya, P., Carothers, J. M., et al.
603 (2021). Portable bacterial CRISPR transcriptional activation enables metabolic engineering in
604 *Pseudomonas putida*. *Metabolic Engineering* 66, 283–295. doi:10.1016/j.ymben.2021.04.002.
- 605 Kim, S. K., Yoon, P. K., Kim, S.-J., Woo, S.-G., Rha, E., Lee, H., et al. (2020). CRISPR
606 interference-mediated gene regulation in *Pseudomonas putida* KT2440. *Microbial Biotechnology*
607 13, 210–221. doi:10.1111/1751-7915.13382.
- 608 Kim, S. K., Kim, H., Ahn, W.-C., Park, K.-H., Woo, E.-J., Lee, D.-H., et al. (2017). Efficient
609 Transcriptional Gene Repression by Type V-A CRISPR-Cpf1 from *Eubacterium eligens*. *ACS*
610 *Synth. Biol.* 6, 1273–1282. doi:10.1021/acssynbio.6b00368.
- 611 Kirtania, P., Hódi, B., Mallick, I., Vass, I. Z., Fehér, T., Vass, I., et al. (2019). A single plasmid based
612 CRISPR interference in *Synechocystis* 6803 – A proof of concept. *PLOS ONE* 14, e0225375.
613 doi:10.1371/journal.pone.0225375.
- 614 Knoops, A., Capelle, F. V., Fontaine, L., Verhaegen, M., Mignolet, J., Goffin, P., et al. (2022). The
615 CovRS Environmental Sensor Directly Controls the ComRS Signaling System To Orchestrate
616 Competence Bimodality in *Salivarius Streptococci*. *mBio*. doi:10.1128/mbio.03125-21.
- 617 Knoot, C. J., Biswas, S., and Pakrasi, H. B. (2020). Tunable Repression of Key Photosynthetic
618 Processes Using Cas12a CRISPR Interference in the Fast-Growing Cyanobacterium
619 *Synechococcus* sp. UTEX 2973. *ACS Synth. Biol.* 9, 132–143. doi:10.1021/acssynbio.9b00417.
- 620 Koonin, E. V., Makarova, K. S., and Zhang, F. (2017). Diversity, classification and evolution of
621 CRISPR-Cas systems. *Current Opinion in Microbiology* 37, 67–78.
622 doi:10.1016/j.mib.2017.05.008.
- 623 Kozaeva, E., Volkova, S., Matos, M. R. A., Mezzina, M. P., Wulff, T., Volke, D. C., et al. (2021).
624 Model-guided dynamic control of essential metabolic nodes boosts acetyl-coenzyme A–
625 dependent bioproduction in rewired *Pseudomonas putida*. *Metabolic Engineering* 67, 373–386.
626 doi:10.1016/j.ymben.2021.07.014.
- 627 Kuo, J., Yuan, R., Sánchez, C., Paulsson, J., and Silver, P. A. (2020). Toward a translationally
628 independent RNA-based synthetic oscillator using deactivated CRISPR-Cas. *Nucleic Acids*
629 *Research* 48, 8165–8177. doi:10.1093/nar/gkaa557.
- 630 Landeta, C., McPartland, L., Tran, N. Q., Meehan, B. M., Zhang, Y., Tanweer, Z., et al. (2019).
631 Inhibition of *Pseudomonas aeruginosa* and *Mycobacterium tuberculosis* disulfide bond forming
632 enzymes. *Molecular Microbiology* 111, 918–937. doi:10.1111/mmi.14185.
- 633 Lee, H. H., Ostrov, N., Wong, B. G., Gold, M. A., Khalil, A. S., and Church, G. M. (2019).
634 Functional genomics of the rapidly replicating bacterium *Vibrio natriegens* by CRISPRi. *Nat*
635 *Microbiol* 4, 1105–1113. doi:10.1038/s41564-019-0423-8.
- 636 Lee, M., and Woo, H. M. (2020). A Logic NAND Gate for Controlling Gene Expression in a
637 Circadian Rhythm in Cyanobacteria. *ACS Synth. Biol.* 9, 3210–3216.
638 doi:10.1021/acssynbio.0c00455.

- 639 Lee, S. S., Shin, H., Jo, S., Lee, S.-M., Um, Y., and Woo, H. M. (2018). Rapid identification of
640 unknown carboxyl esterase activity in *Corynebacterium glutamicum* using RNA-guided CRISPR
641 interference. *Enzyme and Microbial Technology* 114, 63–68.
642 doi:10.1016/j.enzmictec.2018.04.004.
- 643 Leonard, S. P., Perutka, J., Powell, J. E., Geng, P., Richhart, D. D., Byrom, M., et al. (2018). Genetic
644 Engineering of Bee Gut Microbiome Bacteria with a Toolkit for Modular Assembly of Broad-
645 Host-Range Plasmids. *ACS Synth. Biol.* 7, 1279–1290. doi:10.1021/acssynbio.7b00399.
- 646 Lewis, W. H., Tahon, G., Geesink, P., Sousa, D. Z., and Ettema, T. J. G. (2021). Innovations to
647 culturing the uncultured microbial majority. *Nat Rev Microbiol* 19, 225–240.
648 doi:10.1038/s41579-020-00458-8.
- 649 Li, J., Tang, Q., Li, Y., Fan, Y.-Y., Li, F.-H., Wu, J.-H., et al. (2020a). Rediverting Electron Flux
650 with an Engineered CRISPR-ddAsCpf1 System to Enhance the Pollutant Degradation Capacity
651 of *Shewanella oneidensis*. *Environ. Sci. Technol.* 54, 3599–3608. doi:10.1021/acs.est.9b06378.
- 652 Li, J., and Ye, B.-C. (2021). Metabolic engineering of *Pseudomonas putida* KT2440 for high-yield
653 production of protocatechuic acid. *Bioresource Technology* 319, 124239.
654 doi:10.1016/j.biortech.2020.124239.
- 655 Li, L., Wei, K., Zheng, G., Liu, X., Chen, S., Jiang, W., et al. (2018). CRISPR-Cpf1-Assisted
656 Multiplex Genome Editing and Transcriptional Repression in *Streptomyces*. *Applied and*
657 *Environmental Microbiology*. doi:10.1128/AEM.00827-18.
- 658 Li, M., Chen, J., Wang, Y., Liu, J., Huang, J., Chen, N., et al. (2020b). Efficient Multiplex Gene
659 Repression by CRISPR-dCpf1 in *Corynebacterium glutamicum*. *Frontiers in Bioengineering and*
660 *Biotechnology* 8. Available at: <https://www.frontiersin.org/article/10.3389/fbioe.2020.00357>
661 [Accessed February 14, 2022].
- 662 Li, Q., Chen, J., Minton, N. P., Zhang, Y., Wen, Z., Liu, J., et al. (2016). CRISPR-based genome
663 editing and expression control systems in *Clostridium acetobutylicum* and *Clostridium*
664 *beijerinckii*. *Biotechnology Journal* 11, 961–972. doi:10.1002/biot.201600053.
- 665 Li, Z., and Liu, J.-Z. (2017). Transcriptomic Changes in Response to Putrescine Production in
666 Metabolically Engineered *Corynebacterium glutamicum*. *Frontiers in Microbiology* 8. Available
667 at: <https://www.frontiersin.org/article/10.3389/fmicb.2017.01987> [Accessed February 8, 2022].
- 668 Liew, A. T. F., Theis, T., Jensen, S. O., Garcia-Lara, J., Foster, S. J., Firth, N., et al. (2010). A simple
669 plasmid-based system that allows rapid generation of tightly controlled gene expression in
670 *Staphylococcus aureus*. *Microbiology* 157, 666–676. doi:10.1099/mic.0.045146-0.
- 671 Liow, L. T., Go, M. K., Chang, M. W., and Yew, W. S. (2020). Toolkit Development for Cyanogenic
672 and Gold Biorecovery Chassis *Chromobacterium violaceum*. *ACS Synth. Biol.* 9, 953–961.
673 doi:10.1021/acssynbio.0c00064.
- 674 Liu, D., Johnson, V. M., and Pakrasi, H. B. (2020a). A Reversibly Induced CRISPRi System
675 Targeting Photosystem II in the Cyanobacterium *Synechocystis* sp. PCC 6803. *ACS Synth. Biol.*
676 9, 1441–1449. doi:10.1021/acssynbio.0c00106.

- 677 Liu, W., Tang, D., Wang, H., Lian, J., Huang, L., and Xu, Z. (2019a). Combined genome editing and
678 transcriptional repression for metabolic pathway engineering in *Corynebacterium glutamicum*
679 using a catalytically active Cas12a. *Appl Microbiol Biotechnol* 103, 8911–8922.
680 doi:10.1007/s00253-019-10118-4.
- 681 Liu, X., Gallay, C., Kjos, M., Domenech, A., Slager, J., van Kessel, S., et al. (2017). High-throughput
682 CRISPRi phenotyping identifies new essential genes in *Streptococcus pneumoniae*. *Molecular*
683 *Systems Biology* 13, 931. doi:10.15252/msb.20167449.
- 684 Liu, X., Kimmey, J. M., Matarazzo, L., Bakker, V. de, Maele, L. V., Sirard, J.-C., et al. (2021a).
685 Exploration of Bacterial Bottlenecks and *Streptococcus pneumoniae* Pathogenesis by CRISPRi-
686 Seq. *Cell Host & Microbe* 29, 107-120.e6. doi:10.1016/j.chom.2020.10.001.
- 687 Liu, Y., Chen, J., Crisante, D., Jaramillo Lopez, J. M., and Mahadevan, R. (2020b). Dynamic Cell
688 Programming with Quorum Sensing-Controlled CRISPRi Circuit. *ACS Synth. Biol.* 9, 1284–
689 1291. doi:10.1021/acssynbio.0c00148.
- 690 Liu, Y., Khan, S., Wu, P., Li, B., Liu, L., Ni, J., et al. (2021b). Uncovering and Engineering a Mini-
691 Regulatory Network of the TetR-Family Regulator SACE_0303 for Yield Improvement of
692 Erythromycin in *Saccharopolyspora erythraea*. *Frontiers in Bioengineering and Biotechnology* 9.
693 Available at: <https://www.frontiersin.org/article/10.3389/fbioe.2021.692901> [Accessed February
694 1, 2022].
- 695 Liu, Y., Wan, X., and Wang, B. (2019b). Engineered CRISPRa enables programmable eukaryote-like
696 gene activation in bacteria. *Nat Commun* 10, 3693. doi:10.1038/s41467-019-11479-0.
- 697 Liu, Y., Wang, H., Li, S., Zhang, Y., Cheng, X., Xiang, W., et al. (2021c). Engineering of primary
698 metabolic pathways for titer improvement of milbemycins in *Streptomyces bingchenggensis*.
699 *Appl Microbiol Biotechnol* 105, 1875–1887. doi:10.1007/s00253-021-11164-7.
- 700 Lunge, A., Gupta, R., Choudhary, E., and Agarwal, N. (2020). The unfoldase ClpC1 of
701 *Mycobacterium tuberculosis* regulates the expression of a distinct subset of proteins having
702 intrinsically disordered termini. *Journal of Biological Chemistry* 295, 9455–9473.
703 doi:10.1074/jbc.RA120.013456.
- 704 Luo, M. L., Mullis, A. S., Leenay, R. T., and Beisel, C. L. (2015). Repurposing endogenous type I
705 CRISPR-Cas systems for programmable gene repression. *Nucleic Acids Research* 43, 674–681.
706 doi:10.1093/nar/gku971.
- 707 Mai, J., Rao, C., Watt, J., Sun, X., Lin, C., Zhang, L., et al. (2019). *Mycobacterium tuberculosis* 6C
708 sRNA binds multiple mRNA targets via C-rich loops independent of RNA chaperones. *Nucleic*
709 *Acids Research* 47, 4292–4307. doi:10.1093/nar/gkz149.
- 710 Makarova, K. S., Wolf, Y. I., Iranzo, J., Shmakov, S. A., Alkhnbashi, O. S., Brouns, S. J. J., et al.
711 (2020). Evolutionary classification of CRISPR–Cas systems: a burst of class 2 and derived
712 variants. *Nat Rev Microbiol* 18, 67–83. doi:10.1038/s41579-019-0299-x.
- 713 Mariscal, A. M., Kakizawa, S., Hsu, J. Y., Tanaka, K., González-González, L., Broto, A., et al.
714 (2018). Tuning Gene Activity by Inducible and Targeted Regulation of Gene Expression in
715 Minimal Bacterial Cells. *ACS Synth. Biol.* 7, 1538–1552. doi:10.1021/acssynbio.8b00028.

- 716 Mårli, M. T. (2020). Using CRISPR interference to study novel biofilm-associated genes in
717 *Staphylococcus aureus*. 126. Available at: [https://nmbu.brae.unit.no/nmbu-](https://nmbu.brae.unit.no/nmbu-xmlui/handle/11250/2682085)
718 [xmlui/handle/11250/2682085](https://nmbu.brae.unit.no/nmbu-xmlui/handle/11250/2682085) [Accessed January 28, 2022].
- 719 Marraffini, L. A., and Sontheimer, E. J. (2008). CRISPR Interference Limits Horizontal Gene
720 Transfer in *Staphylococci* by Targeting DNA. *Science*. doi:10.1126/science.1165771.
- 721 Marreddy, R. K. R., Wu, X., Sapkota, M., Prior, A. M., Jones, J. A., Sun, D., et al. (2019). The Fatty
722 Acid Synthesis Protein Enoyl-ACP Reductase II (FabK) is a Target for Narrow-Spectrum
723 Antibacterials for *Clostridium difficile* Infection. *ACS Infect. Dis.* 5, 208–217.
724 doi:10.1021/acsinfecdis.8b00205.
- 725 McMackin, E. A. W., Marsden, A. E., and Yahr, T. L. (2019). H-NS Family Members MvaT and
726 MvaU Regulate the *Pseudomonas aeruginosa* Type III Secretion System. *Journal of*
727 *Bacteriology*. doi:10.1128/JB.00054-19.
- 728 McNeil, M. B., and Cook, G. M. (2019). Utilization of CRISPR Interference To Validate MmpL3 as
729 a Drug Target in *Mycobacterium tuberculosis*. *Antimicrobial Agents and Chemotherapy*.
730 doi:10.1128/AAC.00629-19.
- 731 McNeil, M. B., Keighley, L. M., Cook, J. R., Cheung, C.-Y., and Cook, G. M. (2021). CRISPR
732 interference identifies vulnerable cellular pathways with bactericidal phenotypes in
733 *Mycobacterium tuberculosis*. *Molecular Microbiology* 116, 1033–1043. doi:10.1111/mmi.14790.
- 734 McNeil, M. B., Ryburn, H. W. K., Harold, L. K., Tirados, J. F., and Cook, G. M. (2020).
735 Transcriptional Inhibition of the F1F0-Type ATP Synthase Has Bactericidal Consequences on the
736 Viability of *Mycobacteria*. *Antimicrobial Agents and Chemotherapy*. doi:10.1128/AAC.00492-
737 20.
- 738 McNeil, M. B., Ryburn, H. W., Tirados, J., Cheung, C.-Y., and Cook, G. M. (2022). Multiplexed
739 transcriptional repression identifies a network of bactericidal interactions between mycobacterial
740 respiratory complexes. *iScience* 25, 103573. doi:10.1016/j.isci.2021.103573.
- 741 Miao, C., Zhao, H., Qian, L., and Lou, C. (2019). Systematically investigating the key features of the
742 DNase deactivated Cpf1 for tunable transcription regulation in prokaryotic cells. *Synthetic and*
743 *Systems Biotechnology* 4, 1–9. doi:10.1016/j.synbio.2018.11.002.
- 744 Mimee, M., Tucker, A. C., Voigt, C. A., and Lu, T. K. (2015). Programming a Human Commensal
745 Bacterium, *Bacteroides thetaiotaomicron*, to Sense and Respond to Stimuli in the Murine Gut
746 Microbiota. *cells* 1, 62–71. doi:10.1016/j.cels.2015.06.001.
- 747 Mo, X.-H., Zhang, H., Wang, T.-M., Zhang, C., Zhang, C., Xing, X.-H., et al. (2020). Establishment
748 of CRISPR interference in *Methylobacterium extorquens* and application of rapidly mining a new
749 phytoene desaturase involved in carotenoid biosynthesis. *Appl Microbiol Biotechnol* 104, 4515–
750 4532. doi:10.1007/s00253-020-10543-w.
- 751 Monk, I. R., Tree, J. J., Howden, B. P., Stinear, T. P., and Foster, T. J. (2015). Complete Bypass of
752 Restriction Systems for Major *Staphylococcus aureus* Lineages. *mBio*. doi:10.1128/mBio.00308-
753 15.

- 754 Mougiakos, I., Mohanraju, P., Bosma, E. F., Vrouwe, V., Finger Bou, M., Naduthodi, M. I. S., et al.
755 (2017). Characterizing a thermostable Cas9 for bacterial genome editing and silencing. *Nat*
756 *Commun* 8, 1647. doi:10.1038/s41467-017-01591-4.
- 757 Müh, U., Pannullo, A. G., Weiss, D. S., and Ellermeier, C. D. (2019). A Xylose-Inducible Expression
758 System and a CRISPR Interference Plasmid for Targeted Knockdown of Gene Expression in
759 *Clostridioides difficile*. *Journal of Bacteriology*. doi:10.1128/JB.00711-18.
- 760 Myrbråten, I. S., Stamsås, G. A., Chan, H., Angeles, D. M., Knutsen, T. M., Salehian, Z., et al.
761 (2021). SmdA is a novel cell morphology determinant in *Staphylococcus aureus*.
762 2021.11.23.469651. doi:10.1101/2021.11.23.469651.
- 763 Myrbråten, I. S., Wiull, K., Salehian, Z., Håvarstein, L. S., Straume, D., Mathiesen, G., et al. (2019).
764 CRISPR Interference for Rapid Knockdown of Essential Cell Cycle Genes in *Lactobacillus*
765 *plantarum*. *mSphere*. doi:10.1128/mSphere.00007-19.
- 766 Nadolinskaia, N. I., Zamakhaev, M. V., Shumkov, M. S., Armianinova, D. K., Karpov, D. S., and
767 Goncharenko, A. V. (2021). CRISPR Interference of Adenylate Cyclases from *Mycobacterium*
768 *tuberculosis*. *Appl Biochem Microbiol* 57, 421–425. doi:10.1134/S0003683821040128.
- 769 Noirot-Gros, M.-F., Forrester, S., Malato, G., Larsen, P. E., and Noirot, P. (2019). CRISPR
770 interference to interrogate genes that control biofilm formation in *Pseudomonas fluorescens*. *Sci*
771 *Rep* 9, 15954. doi:10.1038/s41598-019-52400-5.
- 772 Nussenzweig, P. M., and Marraffini, L. A. (2020). Molecular Mechanisms of CRISPR-Cas Immunity
773 in Bacteria. *Annual Review of Genetics* 54, 93–120. doi:10.1146/annurev-genet-022120-112523.
- 774 Ouellette, S. P. (2018). Feasibility of a Conditional Knockout System for Chlamydia Based on
775 CRISPR Interference. *Frontiers in Cellular and Infection Microbiology* 8. Available at:
776 <https://www.frontiersin.org/article/10.3389/fcimb.2018.00059> [Accessed January 30, 2022].
- 777 Ouellette, S. P., Blay, E. A., Hatch, N. D., and Fisher-Marvin, L. A. (2021). CRISPR Interference To
778 Inducibly Repress Gene Expression in *Chlamydia trachomatis*. *Infection and Immunity*.
779 doi:10.1128/IAI.00108-21.
- 780 Park, J., Shin, H., Lee, S.-M., Um, Y., and Woo, H. M. (2018). RNA-guided single/double gene
781 repressions in *Corynebacterium glutamicum* using an efficient CRISPR interference and its
782 application to industrial strain. *Microbial Cell Factories* 17, 4. doi:10.1186/s12934-017-0843-1.
- 783 Park, J., Yu, B. J., Choi, J., and Woo, H. M. (2019). Heterologous Production of Squalene from
784 Glucose in Engineered *Corynebacterium glutamicum* Using Multiplex CRISPR Interference and
785 High-Throughput Fermentation. *J. Agric. Food Chem.* 67, 308–319.
786 doi:10.1021/acs.jafc.8b05818.
- 787 Pawluk, A., Davidson, A. R., and Maxwell, K. L. (2018). Anti-CRISPR: discovery, mechanism and
788 function. *Nat Rev Microbiol* 16, 12–17. doi:10.1038/nrmicro.2017.120.
- 789 Peng, R., Wang, Y., Feng, W., Yue, X., Chen, J., Hu, X., et al. (2018). CRISPR/dCas9-mediated
790 transcriptional improvement of the biosynthetic gene cluster for the epothilone production in
791 *Myxococcus xanthus*. *Microbial Cell Factories* 17, 15. doi:10.1186/s12934-018-0867-1.

- 792 Peters, J. M., Koo, B.-M., Patino, R., Heussler, G. E., Hearne, C. C., Qu, J., et al. (2019). Enabling
793 genetic analysis of diverse bacteria with Mobile-CRISPRi. *Nat Microbiol* 4, 244–250.
794 doi:10.1038/s41564-018-0327-z.
- 795 Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., et al. (2013).
796 Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene
797 Expression. *Cell* 152, 1173–1183. doi:10.1016/j.cell.2013.02.022.
- 798 Qin, Z., Yang, Y., Yu, S., Liu, L., Chen, Y., Chen, J., et al. (2021). Repurposing the Endogenous
799 Type I-E CRISPR/Cas System for Gene Repression in *Gluconobacter oxydans* WSH-003. *ACS*
800 *Synth. Biol.* 10, 84–93. doi:10.1021/acssynbio.0c00456.
- 801 Qu, J., Prasad, N. K., Yu, M. A., Chen, S., Lyden, A., Herrera, N., et al. (2019). Modulating
802 Pathogenesis with Mobile-CRISPRi. *Journal of Bacteriology*. doi:10.1128/JB.00304-19.
- 803 Quiñones-Garcia, S., Gilman, R. H., Sheen, P., and Zimic, M. (2021). Silencing of an efflux pump
804 coding gene decreases the efflux rate of pyrazinoic acid in *Mycobacterium smegmatis*.
805 2021.10.29.466536. doi:10.1101/2021.10.29.466536.
- 806 Rahman, K., Jamal, M., Chen, X., Zhou, W., Yang, B., Zou, Y., et al. (2021). Reprogramming
807 *Mycobacterium tuberculosis* CRISPR System for Gene Editing and Genome-wide RNA
808 Interference Screening. *Genomics, Proteomics & Bioinformatics*. doi:10.1016/j.gpb.2021.01.008.
- 809 Randall, S. E., Martini, M. C., Zhou, Y., Joubran, S. R., and Shell, S. S. (2020). MamA essentiality in
810 *Mycobacterium smegmatis* is explained by the presence of an apparent cognate restriction
811 endonuclease. *BMC Research Notes* 13, 462. doi:10.1186/s13104-020-05302-z.
- 812 Rath, D., Amlinger, L., Hoekzema, M., Devulapally, P. R., and Lundgren, M. (2015). Efficient
813 programmable gene silencing by Cascade. *Nucleic Acids Research* 43, 237–246.
814 doi:10.1093/nar/gku1257.
- 815 Riley, L. A., and Guss, A. M. (2021). Approaches to genetic tool development for rapid
816 domestication of non-model microorganisms. *Biotechnol Biofuels* 14, 30. doi:10.1186/s13068-
817 020-01872-z.
- 818 Rock, J. M., Hopkins, F. F., Chavez, A., Diallo, M., Chase, M. R., Gerrick, E. R., et al. (2017).
819 Programmable transcriptional repression in mycobacteria using an orthogonal CRISPR
820 interference platform. *Nat Microbiol* 2, 1–9. doi:10.1038/nmicrobiol.2016.274.
- 821 Santos, M., Pacheco, C. C., Yao, L., Hudson, E. P., and Tamagnini, P. (2021). CRISPRi as a Tool to
822 Repress Multiple Copies of Extracellular Polymeric Substances (EPS)-Related Genes in the
823 *Cyanobacterium Synechocystis* sp. PCC 6803. *Life* 11, 1198. doi:10.3390/life11111198.
- 824 Sato'o, Y., Hisatsune, J., Yu, L., Sakuma, T., Yamamoto, T., and Sugai, M. (2018). Tailor-made
825 gene silencing of *Staphylococcus aureus* clinical isolates by CRISPR interference. *PLOS ONE*
826 13, e0185987. doi:10.1371/journal.pone.0185987.
- 827 Savková, K., Huszár, S., Baráth, P., Pakanová, Z., Kozmon, S., Vancová, M., et al. (2021). An ABC
828 transporter Wzm–Wzt catalyzes translocation of lipid-linked galactan across the plasma
829 membrane in mycobacteria. *PNAS* 118. doi:10.1073/pnas.2023663118.

- 830 Schilling, C., Koffas, M. A. G., Sieber, V., and Schmid, J. (2020). Novel Prokaryotic CRISPR-
831 Cas12a-Based Tool for Programmable Transcriptional Activation and Repression. *ACS Synth.*
832 *Biol.* 9, 3353–3363. doi:10.1021/acssynbio.0c00424.
- 833 Schultenkämper, K., Brito, L. F., López, M. G., Brautaset, T., and Wendisch, V. F. (2019).
834 Establishment and application of CRISPR interference to affect sporulation, hydrogen peroxide
835 detoxification, and mannitol catabolism in the methylotrophic thermophile *Bacillus methanolicus*.
836 *Appl Microbiol Biotechnol* 103, 5879–5889. doi:10.1007/s00253-019-09907-8.
- 837 Schultenkämper, K., Gütle, D. D., López, M. G., Keller, L. B., Zhang, L., Einsle, O., et al. (2021).
838 Interrogating the Role of the Two Distinct Fructose-Bisphosphate Aldolases of *Bacillus*
839 *methanolicus* by Site-Directed Mutagenesis of Key Amino Acids and Gene Repression by
840 CRISPR Interference. *Frontiers in Microbiology* 12. Available at:
841 <https://www.frontiersin.org/article/10.3389/fmicb.2021.669220> [Accessed January 31, 2022].
- 842 Sha, Y., Qiu, Y., Zhu, Y., Sun, T., Luo, Z., Gao, J., et al. (2020). CRISPRi-Based Dynamic
843 Regulation of Hydrolase for the Synthesis of Poly- γ -Glutamic Acid with Variable Molecular
844 Weights. *ACS Synth. Biol.* 9, 2450–2459. doi:10.1021/acssynbio.0c00207.
- 845 Shabestary, K., Anfelt, J., Ljungqvist, E., Jahn, M., Yao, L., and Hudson, E. P. (2018). Targeted
846 Repression of Essential Genes To Arrest Growth and Increase Carbon Partitioning and Biofuel
847 Titrers in *Cyanobacteria*. *ACS Synth. Biol.* 7, 1669–1675. doi:10.1021/acssynbio.8b00056.
- 848 Shabestary, K., Hernández, H. P., Miao, R., Ljungqvist, E., Hallman, O., Sporre, E., et al. (2021).
849 Cycling between growth and production phases increases *cyanobacteria* bioproduction of lactate.
850 *Metabolic Engineering* 68, 131–141. doi:10.1016/j.ymben.2021.09.010.
- 851 Shields, R. C., Walker, A. R., Maricic, N., Chakraborty, B., Underhill, S. A. M., and Burne, R. A.
852 (2020). Repurposing the *Streptococcus mutans* CRISPR-Cas9 System to Understand Essential
853 Gene Function. *PLOS Pathogens* 16, e1008344. doi:10.1371/journal.ppat.1008344.
- 854 Shin, J., Kang, S., Song, Y., Jin, S., Lee, J. S., Lee, J.-K., et al. (2019). Genome Engineering of
855 *Eubacterium limosum* Using Expanded Genetic Tools and the CRISPR-Cas9 System. *ACS Synth.*
856 *Biol.* 8, 2059–2068. doi:10.1021/acssynbio.9b00150.
- 857 Singh, A. K., Carette, X., Potluri, L.-P., Sharp, J. D., Xu, R., Prsic, S., et al. (2016). Investigating
858 essential gene function in *Mycobacterium tuberculosis* using an efficient CRISPR interference
859 system. *Nucleic Acids Research* 44, e143. doi:10.1093/nar/gkw625.
- 860 Singh, K. H., Jha, B., Dwivedy, A., Choudhary, E., N, A. G., Ashraf, A., et al. (2017).
861 Characterization of a secretory hydrolase from *Mycobacterium tuberculosis* sheds critical insight
862 into host lipid utilization by *M. tuberculosis*. *Journal of Biological Chemistry* 292, 11326–11335.
863 doi:10.1074/jbc.M117.794297.
- 864 Son, J., Jang, S. H., Cha, J. W., and Jeong, K. J. (2020). Development of CRISPR Interference
865 (CRISPRi) Platform for Metabolic Engineering of *Leuconostoc citreum* and Its Application for
866 Engineering Riboflavin Biosynthesis. *International Journal of Molecular Sciences* 21, 5614.
867 doi:10.3390/ijms21165614.

- 868 Spoto, M., Fleming, E., Nzutchi, Y. O., Guan, C., and Oh, J. (2021). Large-scale CRISPRi and
869 transcriptomics of *Staphylococcus epidermidis* identify genetic factors implicated in commensal-
870 pathogen lifestyle versatility. 2021.04.29.442003. doi:10.1101/2021.04.29.442003.
- 871 Spoto, M., Guan, C., Fleming, E., and Oh, J. (2020). A Universal, Genomewide GuideFinder for
872 CRISPR/Cas9 Targeting in Microbial Genomes. *mSphere*. doi:10.1128/mSphere.00086-20.
- 873 Stamsås, G. A., Myrbråten, I. S., Straume, D., Salehian, Z., Veening, J.-W., Håvarstein, L. S., et al.
874 (2018). CozEa and CozEb play overlapping and essential roles in controlling cell division in
875 *Staphylococcus aureus*. *Molecular Microbiology* 109, 615–632. doi:10.1111/mmi.13999.
- 876 Stolle, A.-S., Meader, B. T., Toska, J., and Mekalanos, J. J. (2021). Endogenous membrane stress
877 induces T6SS activity in *Pseudomonas aeruginosa*. *PNAS* 118. doi:10.1073/pnas.2018365118.
- 878 Sun, J., Wang, Q., Jiang, Y., Wen, Z., Yang, L., Wu, J., et al. (2018). Genome editing and
879 transcriptional repression in *Pseudomonas putida* KT2440 via the type II CRISPR system.
880 *Microb Cell Fact* 17, 41. doi:10.1186/s12934-018-0887-x.
- 881 Takacs, C. N., Scott, M., Chang, Y., Kloos, Z. A., Irnov, I., Rosa, P. A., et al. (2020). A CRISPR
882 Interference Platform for Selective Downregulation of Gene Expression in *Borrelia burgdorferi*.
883 *Applied and Environmental Microbiology*. doi:10.1128/AEM.02519-20.
- 884 Taketani, M., Zhang, J., Zhang, S., Triassi, A. J., Huang, Y.-J., Griffith, L. G., et al. (2020). Genetic
885 circuit design automation for the gut resident species *Bacteroides thetaiotaomicron*. *Nat*
886 *Biotechnol* 38, 962–969. doi:10.1038/s41587-020-0468-5.
- 887 Tan, S. Z., Reisch, C. R., and Prather, K. L. J. (2018). A Robust CRISPR Interference Gene
888 Repression System in *Pseudomonas*. *Journal of Bacteriology*. doi:10.1128/JB.00575-17.
- 889 Tao, W., Lv, L., and Chen, G.-Q. (2017). Engineering *Halomonas* species TD01 for enhanced
890 polyhydroxyalkanoates synthesis via CRISPRi. *Microbial Cell Factories* 16, 48.
891 doi:10.1186/s12934-017-0655-3.
- 892 Teh, M. Y., Ooi, K. H., Danny Teo, S. X., Bin Mansoor, M. E., Shaun Lim, W. Z., and Tan, M. H.
893 (2019). An Expanded Synthetic Biology Toolkit for Gene Expression Control in
894 *Acetobacteraceae*. *ACS Synth. Biol.* 8, 708–723. doi:10.1021/acssynbio.8b00168.
- 895 Thakur, P., Gantasala, N. P., Choudhary, E., Singh, N., Abdin, M. Z., and Agarwal, N. (2016). The
896 preprotein translocase YidC controls respiratory metabolism in *Mycobacterium tuberculosis*. *Sci*
897 *Rep* 6, 24998. doi:10.1038/srep24998.
- 898 Tian, J., Yang, G., Gu, Y., Sun, X., Lu, Y., and Jiang, W. (2020). Developing an endogenous
899 quorum-sensing based CRISPRi circuit for autonomous and tunable dynamic regulation of
900 multiple targets in *Streptomyces*. *Nucleic Acids Research* 48, 8188–8202.
901 doi:10.1093/nar/gkaa602.
- 902 Tong, Y., Charusanti, P., Zhang, L., Weber, T., and Lee, S. Y. (2015). CRISPR-Cas9 Based
903 Engineering of Actinomycetal Genomes. *ACS Synth. Biol.* 4, 1020–1029.
904 doi:10.1021/acssynbio.5b00038.

- 905 Tong, Y., Whitford, C. M., Blin, K., Jørgensen, T. S., Weber, T., and Lee, S. Y. (2020). CRISPR–
906 Cas9, CRISPRi and CRISPR-BEST-mediated genetic manipulation in streptomycetes. *Nat*
907 *Protoc* 15, 2470–2502. doi:10.1038/s41596-020-0339-z.
- 908 Ultee, E., van der Aart, L. T., Zhang, L., van Dissel, D., Diebolder, C. A., van Wezel, G. P., et al.
909 (2020). Teichoic acids anchor distinct cell wall lamellae in an apically growing bacterium.
910 *Commun Biol* 3, 1–9. doi:10.1038/s42003-020-1038-6.
- 911 Vartoukian, S. R., Palmer, R. M., and Wade, W. G. (2010). Strategies for culture of ‘unculturable’
912 bacteria. *FEMS Microbiology Letters* 309, 1–7. doi:10.1111/j.1574-6968.2010.02000.x.
- 913 Villegas Kcam, M. C., Tsong, A. J., and Chappell, J. (2022). Uncovering the Distinct Properties of a
914 Bacterial Type I-E CRISPR Activation System. *ACS Synth. Biol.* doi:10.1021/acssynbio.1c00496.
- 915 Villegas Kcam, M. C., Tsong, A. J., and Chappell, J. (2021). Rational engineering of a modular
916 bacterial CRISPR–Cas activation platform with expanded target range. *Nucleic Acids Research*
917 49, 4793–4802. doi:10.1093/nar/gkab211.
- 918 Wang, J., Dai, W., Li, J., Li, Q., Xie, R., Zhang, Y., et al. (2021a). AcrHub: an integrative hub for
919 investigating, predicting and mapping anti-CRISPR proteins. *Nucleic Acids Research* 49, D630–
920 D638. doi:10.1093/nar/gkaa951.
- 921 Wang, J., Dai, W., Li, J., Xie, R., Dunstan, R. A., Stubenrauch, C., et al. (2020). PaCRISPR: a server
922 for predicting and visualizing anti-CRISPR proteins. *Nucleic Acids Research* 48, W348–W357.
923 doi:10.1093/nar/gkaa432.
- 924 Wang, J., Zhao, P., Li, Y., Xu, L., and Tian, P. (2018a). Engineering CRISPR interference system in
925 *Klebsiella pneumoniae* for attenuating lactic acid synthesis. *Microbial Cell Factories* 17, 56.
926 doi:10.1186/s12934-018-0903-1.
- 927 Wang, K., and Nicholaou, M. (2017). Suppression of Antimicrobial Resistance in MRSA Using
928 CRISPR-dCas9. *American Society for Clinical Laboratory Science* 30, 207–213.
929 doi:10.29074/ascls.30.4.207.
- 930 Wang, M., Liu, L., Fan, L., and Tan, T. (2017). CRISPRi based system for enhancing 1-butanol
931 production in engineered *Klebsiella pneumoniae*. *Process Biochemistry* 56, 139–146.
932 doi:10.1016/j.procbio.2017.02.013.
- 933 Wang, T., Guan, C., Guo, J., Liu, B., Wu, Y., Xie, Z., et al. (2018b). Pooled CRISPR interference
934 screening enables genome-scale functional genomics study in bacteria with superior performance.
935 *Nat Commun* 9, 2475. doi:10.1038/s41467-018-04899-x.
- 936 Wang, T., Wang, M., Zhang, Q., Cao, S., Li, X., Qi, Z., et al. (2019). Reversible Gene Expression
937 Control in *Yersinia pestis* by Using an Optimized CRISPR Interference System. *Applied and*
938 *Environmental Microbiology*. doi:10.1128/AEM.00097-19.
- 939 Wang, W., and Sun, B. (2021). VraCP regulates cell wall metabolism and antibiotic resistance in
940 vancomycin-intermediate *Staphylococcus aureus* strain Mu50. *Journal of Antimicrobial*
941 *Chemotherapy* 76, 1712–1723. doi:10.1093/jac/dkab113.

- 942 Wang, X., Fu, Y., Wang, M., and Niu, G. (2021b). Synthetic Cellobiose-Inducible Regulatory
943 Systems Allow Tight and Dynamic Controls of Gene Expression in *Streptomyces*. *ACS Synth.*
944 *Biol.* 10, 1956–1965. doi:10.1021/acssynbio.1c00152.
- 945 Wang, Y., Yue, X., Yuan, S., Hong, Y., Hu, W., and Li, Y. (2021c). Internal Promoters and Their
946 Effects on the Transcription of Operon Genes for Epothilone Production in *Myxococcus xanthus*.
947 *Frontiers in Bioengineering and Biotechnology* 9. Available at:
948 <https://www.frontiersin.org/article/10.3389/fbioe.2021.758561> [Accessed February 1, 2022].
- 949 Wang, Y., Zhang, Z.-T., Seo, S.-O., Lynn, P., Lu, T., Jin, Y.-S., et al. (2016). Gene transcription
950 repression in *Clostridium beijerinckii* using CRISPR-dCas9. *Biotechnology and Bioengineering*
951 113, 2739–2743. doi:10.1002/bit.26020.
- 952 Wen, Z., Minton, N. P., Zhang, Y., Li, Q., Liu, J., Jiang, Y., et al. (2017). Enhanced solvent
953 production by metabolic engineering of a twin-clostridial consortium. *Metabolic Engineering* 39,
954 38–48. doi:10.1016/j.ymben.2016.10.013.
- 955 Werner, J. N., Shi, H., Hsin, J., Huang, K. C., Gitai, Z., and Klein, E. A. (2020). AimB Is a Small
956 Protein Regulator of Cell Size and MreB Assembly. *Biophysical Journal* 119, 593–604.
957 doi:10.1016/j.bpj.2020.04.029.
- 958 Wiles, T. J., Schlomann, B. H., Wall, E. S., Betancourt, R., Parthasarathy, R., and Guillemin, K.
959 (2020). Swimming motility of a gut bacterial symbiont promotes resistance to intestinal expulsion
960 and enhances inflammation. *PLOS Biology* 18, e3000661. doi:10.1371/journal.pbio.3000661.
- 961 Woolston, B. M., Emerson, D. F., Currie, D. H., and Stephanopoulos, G. (2018). Rediverting carbon
962 flux in *Clostridium ljungdahlii* using CRISPR interference (CRISPRi). *Metabolic Engineering*
963 48, 243–253. doi:10.1016/j.ymben.2018.06.006.
- 964 Wu, J., Cheng, Z.-H., Min, D., Cheng, L., He, R.-L., Liu, D.-F., et al. (2020). CRISPRi System as an
965 Efficient, Simple Platform for Rapid Identification of Genes Involved in Pollutant
966 Transformation by *Aeromonas hydrophila*. *Environ. Sci. Technol.* 54, 3306–3315.
967 doi:10.1021/acs.est.9b07191.
- 968 Wu, X., Zha, J., Koffas, M. A. G., and Dordick, J. S. (2019). Reducing *Staphylococcus aureus*
969 resistance to lysostaphin using CRISPR-dCas9. *Biotechnology and Bioengineering* 116, 3149–
970 3159. doi:10.1002/bit.27143.
- 971 Wurihan, W., Huang, Y., Weber, A. M., Wu, X., and Fan, H. (2019). Nonspecific toxicities of
972 *Streptococcus pyogenes* and *Staphylococcus aureus* dCas9 in *Chlamydia trachomatis*. *Pathogens*
973 *and Disease* 77, ftaa005. doi:10.1093/femspd/ftaa005.
- 974 Xiang, L., Qi, F., Jiang, L., Tan, J., Deng, C., Wei, Z., et al. (2020). CRISPR-dCas9-mediated
975 knockdown of prtR, an essential gene in *Pseudomonas aeruginosa*. *Letters in Applied*
976 *Microbiology* 71, 386–393. doi:10.1111/lam.13337.
- 977 Xiao, J., Jia, H., Pan, L., Li, Z., Lv, L., Du, B., et al. (2019). Application of the CRISPRi system to
978 repress sepF expression in *Mycobacterium smegmatis*. *Infection, Genetics and Evolution* 72,
979 183–190. doi:10.1016/j.meegid.2018.06.033.

- 980 Xiong, Z.-Q., Wei, Y.-Y., Kong, L.-H., Song, X., Yi, H.-X., and Ai, L.-Z. (2020). Short
981 communication: An inducible CRISPR/dCas9 gene repression system in *Lactococcus lactis*.
982 *Journal of Dairy Science* 103, 161–165. doi:10.3168/jds.2019-17346.
- 983 Xu, Z., Li, Y., Cao, H., Si, M., Zhang, G., Woo, P. C. Y., et al. (2021). A transferrable and
984 integrative type I-F Cascade for heterologous genome editing and transcription modulation.
985 *Nucleic Acids Research* 49, e94. doi:10.1093/nar/gkab521.
- 986 Yamada, S., Suzuki, Y., Kouzuma, A., and Watanabe, K. (2022). Development of a CRISPR
987 interference system for selective gene knockdown in *Acidithiobacillus ferrooxidans*. *Journal of*
988 *Bioscience and Bioengineering* 133, 105–109. doi:10.1016/j.jbiosc.2021.10.012.
- 989 Yan, Y.-S., Yang, Y.-Q., Zou, L.-S., Zhang, L., and Xia, H.-Y. (2022). MilR3, a Unique SARP
990 Family Pleiotropic Regulator in *Streptomyces Bingchengensis*. doi:10.21203/rs.3.rs-
991 1248187/v1.
- 992 Yao, L., Cengic, I., Anfelt, J., and Hudson, E. P. (2016). Multiple Gene Repression in Cyanobacteria
993 Using CRISPRi. *ACS Synth. Biol.* 5, 207–212. doi:10.1021/acssynbio.5b00264.
- 994 Yao, L., Shabestary, K., Björk, S. M., Asplund-Samuelsson, J., Joensson, H. N., Jahn, M., et al.
995 (2020). Pooled CRISPRi screening of the cyanobacterium *Synechocystis* sp PCC 6803 for
996 enhanced industrial phenotypes. *Nat Commun* 11, 1666. doi:10.1038/s41467-020-15491-7.
- 997 Ye, W., Liu, T., Zhu, M., Zhang, W., Huang, Z., Li, S., et al. (2019). An Easy and Efficient Strategy
998 for the Enhancement of Epothilone Production Mediated by TALE-TF and CRISPR/dcas9
999 Systems in *Sorangium cellulosum*. *Frontiers in Bioengineering and Biotechnology* 7. Available
1000 at: <https://www.frontiersin.org/article/10.3389/fbioe.2019.00334> [Accessed February 1, 2022].
- 1001 Yi, Y.-C., and Ng, I.-S. (2021). Redirection of metabolic flux in *Shewanella oneidensis* MR-1 by
1002 CRISPRi and modular design for 5-aminolevulinic acid production. *Bioresources and*
1003 *Bioprocessing* 8, 13. doi:10.1186/s40643-021-00366-6.
- 1004 Yoon, J., and Woo, H. M. (2018). CRISPR interference–mediated metabolic engineering of
1005 *Corynebacterium glutamicum* for homo-butyrate production. *Biotechnology and Bioengineering*
1006 115, 2067–2074. doi:10.1002/bit.26720.
- 1007 Yu, L., Su, W., Fey, P. D., Liu, F., and Du, L. (2018). Yield Improvement of the Anti-MRSA
1008 Antibiotics WAP-8294A by CRISPR/dCas9 Combined with Refactoring Self-Protection Genes in
1009 *Lysobacter enzymogenes* OH11. *ACS Synth. Biol.* 7, 258–266. doi:10.1021/acssynbio.7b00293.
- 1010 Yunus, I. S., Anfelt, J., Sporre, E., Miao, R., Hudson, E. P., and Jones, P. R. (2022). Synthetic
1011 metabolic pathways for conversion of CO₂ into secreted short-to medium-chain hydrocarbons
1012 using cyanobacteria. *Metabolic Engineering*. doi:10.1016/j.ymben.2022.01.017.
- 1013 Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler,
1014 P., et al. (2015). Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System.
1015 *Cell* 163, 759–771. doi:10.1016/j.cell.2015.09.038.

- 1016 Zhan, Y., Xu, Y., Zheng, P., He, M., Sun, S., Wang, D., et al. (2020). Establishment and application
1017 of multiplexed CRISPR interference system in *Bacillus licheniformis*. *Appl Microbiol Biotechnol*
1018 104, 391–403. doi:10.1007/s00253-019-10230-5.
- 1019 Zhang, B., Liu, Z.-Q., Liu, C., and Zheng, Y.-G. (2016). Application of CRISPRi in
1020 *Corynebacterium glutamicum* for shikimic acid production. *Biotechnol Lett* 38, 2153–2161.
1021 doi:10.1007/s10529-016-2207-z.
- 1022 Zhang, K., Zhang, Z., Kang, J., Chen, J., Liu, J., Gao, N., et al. (2020a). CRISPR/Cas13d-Mediated
1023 Microbial RNA Knockdown. *Frontiers in Bioengineering and Biotechnology* 8. Available at:
1024 <https://www.frontiersin.org/article/10.3389/fbioe.2020.00856> [Accessed January 24, 2022].
- 1025 Zhang, L., Ramijan, K., Carrión, V. J., Aart, L. T. van der, Willemse, J., Wezel, G. P. van, et al.
1026 (2021). An Alternative and Conserved Cell Wall Enzyme That Can Substitute for the Lipid II
1027 Synthase MurG. *mBio*. doi:10.1128/mBio.03381-20.
- 1028 Zhang, L., Willemse, J., Yagüe, P., Waal, E. de, Claessen, D., and Wezel, G. P. van (2020b).
1029 Branching of sporogenic aerial hyphae in *sflA* and *sflB* mutants of *Streptomyces coelicolor*
1030 correlates to ectopic localization of DivIVA and FtsZ in time and space. 2020.12.26.424426.
1031 doi:10.1101/2020.12.26.424426.
- 1032 Zhang, S., and Voigt, C. A. (2018). Engineered dCas9 with reduced toxicity in bacteria: implications
1033 for genetic circuit design. *Nucleic Acids Research* 46, 11115–11125. doi:10.1093/nar/gky884.
- 1034 Zhang, X., Wang, J., Cheng, Q., Zheng, X., Zhao, G., and Wang, J. (2017). Multiplex gene regulation
1035 by CRISPR-ddCpf1. *Cell Discov* 3, 1–9. doi:10.1038/celldisc.2017.18.
- 1036 Zhang, Y., and Yuan, J. (2021). CRISPR/Cas12a-mediated genome engineering in the photosynthetic
1037 bacterium *Rhodobacter capsulatus*. *Microbial Biotechnology* 14, 2700–2710. doi:10.1111/1751-
1038 7915.13805.
- 1039 Zhao, C., Shu, X., and Sun, B. (2017). Construction of a Gene Knockdown System Based on
1040 Catalytically Inactive (“Dead”) Cas9 (dCas9) in *Staphylococcus aureus*. *Applied and*
1041 *Environmental Microbiology*. doi:10.1128/AEM.00291-17.
- 1042 Zhao, R., Liu, Y., Zhang, H., Chai, C., Wang, J., Jiang, W., et al. (2019). CRISPR-Cas12a-Mediated
1043 Gene Deletion and Regulation in *Clostridium ljungdahlii* and Its Application in Carbon Flux
1044 Redirection in Synthesis Gas Fermentation. *ACS Synth. Biol.* 8, 2270–2279.
1045 doi:10.1021/acssynbio.9b00033.
- 1046 Zhao, X., Zheng, H., Zhen, J., Shu, W., Yang, S., Xu, J., et al. (2020). Multiplex genetic engineering
1047 improves endogenous expression of mesophilic α -amylase gene in a wild strain *Bacillus*
1048 *amyloliquefaciens* 205. *International Journal of Biological Macromolecules* 165, 609–618.
1049 doi:10.1016/j.ijbiomac.2020.09.210.
- 1050 Zhao, Y., Li, L., Zheng, G., Jiang, W., Deng, Z., Wang, Z., et al. (2018). CRISPR/dCas9-Mediated
1051 Multiplex Gene Repression in *Streptomyces*. *Biotechnology Journal* 13, 1800121.
1052 doi:10.1002/biot.201800121.

1053 Zheng, Y., Han, J., Wang, B., Hu, X., Li, R., Shen, W., et al. (2019). Characterization and
1054 repurposing of the endogenous Type I-F CRISPR–Cas system of *Zymomonas mobilis* for
1055 genome engineering. *Nucleic Acids Research* 47, 11461–11475. doi:10.1093/nar/gkz940.

1056

1057 **7 Supplementary Material**

1058 Tables S1 and S2 are provided in the Supplementary Material file (.xlsx).

1059

1060 8 Table 1. CRISPRi/a studies in non-model bacteria and their key characteristics.

Bacterium	Application	CRISPRi/a	CRISPR System(s) ^a	GW ^b	References ^c and type of study
<u>Actinomycetota</u>					
<i>Bifidobacterium</i> spp.	probiotic	CRISPRi	As dCas12a	N	TD: (Jin et al., 2022)
<i>Corynebacterium glutamicum</i>	bioproduction	CRISPRa	Fn dCas12a- ω	N	TD: (Liu et al., 2019a)
		CRISPRi	Fn dCas12a	N	TD: (Liu et al., 2019a; Li et al., 2020b); ME: (Liu et al., 2019a; Li et al., 2020b; Huang et al., 2021)
			Sp dCas9	N	TD: (Cleto et al., 2016; Zhang et al., 2016; Park et al., 2018; Gauttam et al., 2019); MGF: (Li and Liu, 2017; Lee et al., 2018); ME: (Cleto et al., 2016; Zhang et al., 2016; Park et al., 2018, 2019; Yoon and Woo, 2018; Gauttam et al., 2019)
				N*	SS: (Göttl et al., 2021)
			Rf Cas13d	N	TD: (Zhang et al., 2020a)
<u>Mycobacterium</u>					
<i>M. smegmatis</i> , <i>M. tuberculosis</i>	pathogen	CRISPRi	Fn dCas12a	N	TD: (Fleck and Grundner, 2021)
<i>M. smegmatis</i> , <i>M. tuberculosis</i> , <i>M. bovis</i>	pathogen	CRISPRi	Sp dCas9	N	TD: (Choudhary et al., 2015; Singh et al., 2016; Xiao et al., 2019; Agarwal, 2020; Nadolinskaia et al., 2021); MGF: (Thakur et al., 2016; Singh et al., 2017; Choudhary et al., 2019; Dutta et al., 2019; Agarwal, 2020; Lunge et al., 2020; Faulkner et al., 2021; Gani et al., 2021; Gibson et al., 2021)
<i>M. smegmatis</i> , <i>M. tuberculosis</i>	pathogen	CRISPRi	Sth1 dCas9	N	TD: (Rock et al., 2017; Cheung et al., 2021; Judd et al., 2021); MGF: (Baranowski et al., 2018; Landeta et al., 2019; Mai et al., 2019; McNeil and Cook, 2019; McNeil et al., 2020, 2022; Randall et al., 2020; Brzostek et al., 2021; Quiñones-Garcia et al., 2021; Savková et al., 2021)
				N*	SS: (de Wet et al., 2020; McNeil et al., 2021)
				Y	SS: (Bosch et al., 2021)
<i>M. tuberculosis</i>	pathogen	CRISPRi	Native Type III-A	Y	TD: (Rahman et al., 2021); SS: (Rahman et al., 2021)
<i>Rhodococcus opacus</i>	bioproduction	CRISPRi	Sth1 dCas9	N	TD: (DeLorenzo et al., 2018, 2021); ME: (DeLorenzo et al., 2018)
<i>Saccharopolyspora erythraea</i>	bioproduction, bioresearch	CRISPRi	Sp dCas9	N	ME: (Liu et al., 2021b)
<u>Streptomyces</u>					
<i>S. venezuelae</i>	bioproduction, bioresearch	CRISPRa	Sp dCas9- α NTD	N	TD: (Ameruso et al., 2021)
<i>S. coelicolor</i>	bioproduction, bioresearch	CRISPRi	Fn dCas12a	N	TD: (Li et al., 2018); MGF: (Yan et al., 2022); ME: (Liu et al., 2021c)
<i>S. coelicolor</i> , <i>S. venezuelae</i> , <i>S. rapamycinicus</i> , <i>S. spp.</i>	bioproduction, bioresearch	CRISPRi	Sp dCas9	N	TD: (Tong et al., 2015, 2020; Zhao et al., 2018; Tian et al., 2020; Ameruso et al., 2021; Wang et al., 2021a); ME: (Tian et al., 2020); MGF: (Ultee et al., 2020; Zhang et al., 2020b, 2021); TRN: (Tian et al., 2020)
<u>Bacteroidetes</u>					
<i>Bacteroides thetaiotaomicron</i>	probiotic	CRISPRi	Sp dCas9	N	TD: (Mimee et al., 2015), TRN: (Mimee et al., 2015; Taketani et al., 2020)
<i>Bacteroides</i> , <i>Parabacteroides</i> , <i>Prevotella</i> spp.	probiotic	CRISPRi	As dCas12a	N	TD: (Jin et al., 2022)
<u>Chlamydiae</u>					

Non-Model Bacteria CRISPR-Based Gene Regulation

<i>Chlamydia trachomatis</i>	pathogen	CRISPRi	As dCas12a Sa dCas9	N N	TD: (Ouellette et al., 2021) TD: (Ouellette, 2018; Wurihan et al., 2019; Ouellette et al., 2021); MGF: (Brockett et al., 2021)
Cyanobacteria					
<i>Anabaena</i> sp. PCC 7120	bioproduction, bioresearch	CRISPRi	Sp dCas9	N	TD: (Higo et al., 2018; Higo and Ehira, 2019); ME: (Higo et al., 2018; Higo and Ehira, 2019); MGF: (Higo et al., 2019)
<i>Synechococcus</i> sp. UTEX 2973	bioproduction	CRISPRi	Fn dCas12a	N	TD: (Knoot et al., 2020); MGF: (Knoot et al., 2020)
<i>Synechococcus elongatus</i>	bioproduction	CRISPRi	Fn dCas12a	N	TD: (Choi and Woo, 2020); ME: (Choi and Woo, 2020)
			Sp dCas9	N	TD: (Huang et al., 2016); ME: (Huang et al., 2016); TRN: (Lee and Woo, 2020)
<i>Synechococcus</i> sp. PCC 7002	bioproduction	CRISPRi	Sp dCas9	N	TD: (Gordon et al., 2016); ME: (Gordon et al., 2016)
<i>Synechocystis</i> sp. PCC 6803	bioproduction, bioresearch	CRISPRi	Fn dCas12a	N	TD: (Liu et al., 2020a); MGF: (Liu et al., 2020a)
			Sp dCas9	N	TD: (Yao et al., 2016; Kirtania et al., 2019); MGF: (Behler et al., 2018; Kaczmarzyk et al., 2018; Behle et al., 2021, 3; Santos et al., 2021; Shabestary et al., 2021); ME: (Kaczmarzyk et al., 2018; Shabestary et al., 2018, 2021; Dietsch et al., 2021; Yunus et al., 2022)
				Y	SS: (Yao et al., 2020)
Firmicutes					
Bacillus					
<i>B. amyloliquefaciens</i>	bioproduction	CRISPRa	Sp dCas9- ω	N	TD: (Zhao et al., 2020); ME: (Zhao et al., 2020)
<i>B. amyloliquefaciens</i> , <i>B. methanolicus</i> , <i>B. licheniformis</i>	bioproduction	CRISPRi	Sp dCas9	N	TD: (Schultenkämper et al., 2019; Sha et al., 2020; Zhan et al., 2020; Zhao et al., 2020); MGF: (Schultenkämper et al., 2019, 2021); ME: (Sha et al., 2020; Zhan et al., 2020)
<i>B. smithii</i>	bioproduction	CRISPRi	ThermodCas9	N	TD: (Mougiakos et al., 2017)
<i>Clostridioides difficile</i>	pathogen	CRISPRi	Sp dCas9	N	TD: (Marreddy et al., 2019; Müh et al., 2019); MGF: (Marreddy et al., 2019; Müh et al., 2019)
Clostridium					
<i>C. sporogenes</i> , <i>C. spp.</i>	probiotic	CRISPRi	As dCas12a	N	TD: (Jin et al., 2022)
<i>C. ljungdahlii</i>	bioproduction	CRISPRi	Fn dCas12a	N	TD: (Zhao et al., 2019); ME: (Zhao et al., 2019)
<i>C. autoethanogenum</i> , <i>C. acetobutylicum</i> , <i>C. beijerinckii</i> , <i>C. pasteurianum</i> , <i>C. cellulovorans</i> , <i>C. ljungdahlii</i>	bioproduction	CRISPRi	Sp dCas9	N	TD: (Bruder et al., 2016; Li et al., 2016; Wang et al., 2016; Wen et al., 2017; Woolston et al., 2018; Fackler et al., 2021); ME: (Wen et al., 2017; Woolston et al., 2018)
<i>Enterococcus faecalis</i>	pathogen	CRISPRi	Sp dCas9	N	TD: (Peters et al., 2019; Afonina et al., 2020); MGF: (Afonina et al., 2020)
<i>Eubacterium limosum</i>	bioproduction, probiotic	CRISPRi	Sp dCas9	N	TD: (Shin et al., 2019)
<i>Hungateiclostridium thermocellum</i>	bioproduction	CRISPRi	ThermodCas9	N	TD: (Ganguly et al., 2020)
<i>Lactiplantibacillus plantarum</i>	probiotic, bioproduction	CRISPRi	Sp dCas9	N	TD: (Myrbråten et al., 2019); MGF: (Myrbråten et al., 2019)
<i>Lactococcus lactis</i>	probiotic, bioproduction	CRISPRi	Sp dCas9	N	TD: (Berlec et al., 2018; Xiong et al., 2020)
<i>Leuconostoc citreum</i>	probiotic	CRISPRi	Sp dCas9	N	TD: (Son et al., 2020); ME: (Son et al., 2020)
<i>Listeria monocytogenes</i>	pathogen	CRISPRi	Sp dCas9	N	TD: (Peters et al., 2019)

Non-Model Bacteria CRISPR-Based Gene Regulation

<i>Paenibacillus polymyxa</i>	bioproduction	CRISPRa	As dCas12a-SoxS	N	TD: (Schilling et al., 2020), ME: (Schilling et al., 2020)
<i>Paenibacillus sonchi</i>	plant symbiote	CRISPRi	Sp dCas9	N	TD: (Brito et al., 2020)
<i>Staphylococcus aureus</i> , <i>S. epidermidis</i>	pathogen	CRISPRi	Sp dCas9	N	TD: (Chen et al., 2017; Dong et al., 2017; Zhao et al., 2017; Sato'o et al., 2018; Stamsås et al., 2018; Peters et al., 2019; Depardieu and Bikard, 2020; Jiang et al., 2020; Spoto et al., 2020); MGF: (Wang and Nicholaou, 2017; Stamsås et al., 2018; Wu et al., 2019; Gelin et al., 2020; Mårli, 2020; Gallay et al., 2021; Myrbråten et al., 2021; Wang and Sun, 2021) SS: (Jiang et al., 2020; Mårli, 2020; Spoto et al., 2021)
<i>Streptococcus</i>				Y	
<i>S. pneumoniae</i> , <i>S. salivarius</i>	pathogen	CRISPRi	Sp dCas9	N	TD: (Bikard et al., 2013; Liu et al., 2017); MGF: (Domenech et al., 2018; Gallay et al., 2021; Knoops et al., 2022)
<i>S. pneumoniae</i>	pathogen	CRISPRi	Sp dCas9	N*	SS: (Liu et al., 2017)
				Y	SS: (Dewachter et al., 2021; Gallay et al., 2021; Liu et al., 2021a; de Bakker et al., 2022)
<i>S. agalactiae</i>	pathogen	CRISPRi	Native dCas9	N	TD: (Dammann et al., 2021); MGF: (Dammann et al., 2021)
<i>S. mutans</i>	pathogen	CRISPRi	Native dCas9	N*	TD: (Shields et al., 2020); SS: (Shields et al., 2020)
<u>Proteobacteria</u>					
<i>Acidithiobacillus ferrooxidans</i>	bioresearch, bioremediation	CRISPRi	Sp dCas9	N	TD: (Yamada et al., 2022)
<i>Acinetobacter baumannii</i> , <i>A. baylyi</i>	pathogen	CRISPRi	Sp dCas9	N	TD: (Geng et al., 2019; Peters et al., 2019; Bai et al., 2021); MGF: (Bai et al., 2021; Colquhoun et al., 2021; Dai et al., 2021)
<i>Aeromonas hydrophila</i>	bioproduction, bioresearch, bioremediation	CRISPRi	Sp dCas9	N	TD: (Wu et al., 2020); MGF: (Wu et al., 2020)
<i>Bartonella apis</i>	bee probiotic	CRISPRi	Sp dCas9	N	TD: (Leonard et al., 2018)
<i>Burkholderia cenocepacia</i> , <i>B. multivorans</i> , <i>B. thailandensis</i>	pathogen	CRISPRi	Sp dCas9	N	TD: (Hogan et al., 2019)
<i>Caulobacter crescentus</i>	bioresearch	CRISPRi	Spa dCas9, SthI dCas9	N	TD: (Guzzo et al., 2020)
			Sp dCas9	N	TD: (Irnov et al., 2017); MGF: (Irnov et al., 2017; Werner et al., 2020)
<i>Chromobacterium violaceum</i>	biorecovery	CRISPRi	Sp dCas9	N	TD: (Liow et al., 2020)
<i>Enterobacter cloacae</i>	pathogen	CRISPRi	Sp dCas9	N	TD: (Peters et al., 2019)
<i>Gluconobacter oxydans</i>	bioproduction	CRISPRi	Native Type I-E	N	TD: (Qin et al., 2021)
<i>Halomonas</i> sp. TD01	bioproduction	CRISPRi	Sp dCas9	N	TD: (Tao et al., 2017); ME: (Tao et al., 2017)
<i>Klebsiella</i>					
<i>K. oxytoca</i>	pathogen	CRISPRa	Sp dxCas9	N	TD: (Liu et al., 2019b)
			Sp dCas9-AsiA v2.1	N	TD: (Ho et al., 2020)
<i>K. pneumoniae</i> , <i>K. oxytoca</i> , <i>K. aerogenes</i>	pathogen, bioproduction	CRISPRi	Sp dCas9	N	TD: (Wang et al., 2018; Peters et al., 2019; Ho et al., 2020); ME: (Wang et al., 2017, 2018)
<i>Komagataeibacter hansenii</i> , <i>K. xylinus</i>	bioproduction	CRISPRi	Sp dCas9	N	TD: (Teh et al., 2019; Huang et al., 2020); MGF: (Huang et al., 2020); ME: (Huang et al., 2020)
<i>Legionella pneumophila</i>	pathogen	CRISPRi	Sp dCas9	N	TD: (Ellis et al., 2021); MGF: (Ellis et al., 2021)
<i>Lysobacter enzymogenes</i>	bioproduction, bioresearch	CRISPRa	Sp dCas9-ω	N	TD: (Yu et al., 2018, 11); ME: (Yu et al., 2018, 11)
<i>Methylobacterium extorquens</i>	bioproduction	CRISPRi	Sp dCas9	N	TD: (Mo et al., 2020); MGF: (Mo et al., 2020); ME: (Mo et al., 2020)

Non-Model Bacteria CRISPR-Based Gene Regulation


<i>Myxococcus xanthus</i>	bioproduction	CRISPRa	Sp dCas9- ω	N	TD: (Peng et al., 2018; Wang et al., 2021b); MGF: (Peng et al., 2018; Wang et al., 2021b); ME: (Peng et al., 2018; Wang et al., 2021b) TD: (Ke et al., 2021); MGF: (Ke et al., 2021)
<i>Photorhabdus luminescens</i>	bioresearch	CRISPRa	Sp dCas9- ω	N	
<i>Proteus mirabilis</i>	pathogen	CRISPRi	Sp dCas9	N	TD: (Peters et al., 2019)
<i>Pseudomonas putida</i>	bioproduction, bioremediation	CRISPRa/i	Sp dCas9+MCP	N	TD: (Kiattisewee et al., 2021), ME: (Kiattisewee et al., 2021)
		CRISPRi	Fn dCas12a	N	ME: (Banerjee et al., 2020; Czajka et al., 2021)
<i>P. putida</i> , <i>P. fluorescens</i>	bioproduction, plant symbiote, bioremediation	CRISPRi	Spa dCas9	N	TD: (Tan et al., 2018); MGF: (Gauttam et al., 2021)
			Sp dCas9	N	TD: (Sun et al., 2018; Noiroot-Gros et al., 2019; Batianis et al., 2020; Kim et al., 2020); MGF: (Noiroot-Gros et al., 2019); ME: (Kim et al., 2020; Kozaeva et al., 2021; Li and Ye, 2021); TRN: (Liu et al., 2020b)
<i>P. aeruginosa</i>	pathogen	CRISPRi	Spa dCas9	N	TD: (McMackin et al., 2019; Gauttam et al., 2021); MGF: (McMackin et al., 2019; Gauttam et al., 2021)
			Sp dCas9	N	TD: (Peters et al., 2019; Xiang et al., 2020; Stolle et al., 2021)
			Sp dCas9, Sth1 dCas9	N	TD: (Qu et al., 2019); MGF: (Qu et al., 2019)
<i>Rhodobacter capsulatus</i>	bioproduction	CRISPRi	Native Type I-F	N	TD: (Xu et al., 2021)
			Fn dCas12a	N	TD: (Zhang and Yuan, 2021)
<i>Salmonella enterica</i>	pathogen	CRISPRa/i	Sp dCas9- ω	N	TD: (Bhokisham et al., 2020), TRN: (Bhokisham et al., 2020)
		CRISPRa	Sp dCas9-AsiA v2.1	N	TD: (Ho et al., 2020)
		CRISPRi	Sp dCas9	N	TD: (Peters et al., 2019; Ho et al., 2020)
<i>Shewanella oneidensis</i>	bioproduction, bioresearch	CRISPRi	Ec Type I-E	N	TD: (Rath et al., 2015)
			As dCas12a	N	TD: (Li et al., 2020a); MGF: (Li et al., 2020a)
<i>Sorangium cellulosum</i>	bioresearch	CRISPRa	Sp dCas9	N	TD: (Cao et al., 2017); ME: (Yi and Ng, 2021)
			Sp dCas9-VP64	N	TD: (Ye et al., 2019); MGF: (Ye et al., 2019)
<i>Vibrio casei</i>	bioproduction	CRISPRi	Sp dCas9	N	TD: (Peters et al., 2019)
<i>Vibrio natriegens</i>	bioproduction	CRISPRi	Sp dCas9	Y	TD: (Lee et al., 2019); SS: (Lee et al., 2019)
<i>Vibrio cholerae</i>	pathogen	CRISPRi	Sp dCas9	N	TD: (Caro et al., 2019; Wiles et al., 2020); MGF: (Caro et al., 2019; Wiles et al., 2020)
<i>Yersinia pestis</i>	pathogen	CRISPRi	Sp dCas9	N	TD: (Wang et al., 2019)
<i>Zymomonas mobilis</i>	bioproduction	CRISPRi	Sp dCas9	N	TD: (Banta et al., 2020); MGF: (Banta et al., 2020)
			Native Type I-F	N	TD: (Zheng et al., 2019)
<u>Spirochaetes</u>					
<i>Borrelia burgdorferi</i>	pathogen	CRISPRi	Sp dCas9	N	TD: (Takacs et al., 2020)
<i>Leptospira interrogans</i> , <i>L. biflexa</i> , <i>L. strain LGVF02</i>	pathogen	CRISPRi	Sp dCas9	N	TD: (Fernandes et al., 2019, 2021a, 2021b); MGF: (Fernandes et al., 2021b)
<u>Tenericutes</u>					
<i>Mycoplasma pneumoniae</i> , <i>M. JCVI-syn1.0</i> , <i>M. JCVI-syn3.0</i>	synthetic cells	CRISPRi	Sp dCas9	N	TD: (Mariscal et al., 2018)

1061 ^aAcronyms for each CRISPR system can be found in Table S2.

1062 ^bGenome-wide (GW) classification for the relative size of the gRNA library: yes (Y) indicates a genome-wide library
1063 targeting >90% of coding genes on the genome; no (N) indicates a library of < 50 target genes; and a smaller library
1064 targeting >50 genes but <90% of genome is indicated (N*)

1065 ^cClassifications for types of studies: tool development (TD), mapping gene function (MGF), metabolic engineering (ME),
1066 screens and/or selections (SS), transcriptional regulatory network (TRN).

1067 9 Figures



1068

Figure 1. Applications of CRISPRi/a tools in bacteria. **(A)** CRISPRi/a tools can be used to study gene function by targeting a gene for repression or activation and assaying phenotypic differences under a given condition. **(B)** CRISPRi/a can control transcription regulatory networks through the expression of multiple guide RNAs and a single deactivated Cas (dCas) protein. By incorporating inducible promoters for the guide RNAs (gRNAs) and/or dCas protein, dynamic genetic circuits can be created that respond to multiple input stimuli to alter the expression of output genes, such as a gene of interest (GOI) and a reporter gene. **(C)** CRISPRi/a can be used for dynamic metabolic engineering by regulating gene expression to redirect carbon flux towards production of a desired biochemical, such as using CRISPRi to repress genes encoding competing enzymes (dashed arrows) while using CRISPRa to activate genes for the desired biochemical production (bold arrow). **(D)** CRISPRi/a has been used for high-throughput, large-scale screens and selections ranging from targeted sets of genes to genome-wide libraries. After designing and assembling the gRNA library for the given application, the library is transformed into bacteria that express the cognate dCas protein in either a mixed pooled (i.e., cells containing different gRNA(s) are mixed together) or an individual array format (i.e., cells containing different gRNA(s) are cultured separately). The resulting pooled cell library can be used in competitive selections for functional genomics analyses by applying selective conditions and measuring the relative gRNA fitness. An arrayed cell library can be assayed one-by-one to determine the relationship between strain activity (e.g. production or phenotype) and gene repression/activation.